Document:

License Agreement

 Exhibit 10.5 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 
 LICENSE AGREEMENT 
 This LICENSE AGREEMENT (the “Agreement”), effective as of March 31, 2011 (the “Effective Date”), is made by and between Sunesis Pharmaceuticals, Inc., a Delaware corporation,
having a principal place of business at 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080 (“Sunesis”), and Millennium Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 40 Landsdowne
Street, Cambridge, Massachusetts 02139 (“Millennium”). Sunesis and Millennium are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

BACKGROUND 
 A. Sunesis has developed proprietary technology and know-how for the discovery and optimization of small molecules that bind to enzyme targets and protein-protein interfaces, with special expertise
towards kinases. 
 B. Pursuant to a Collaboration Agreement effective as of August 27, 2004 (the “Original Agreement
Effective Date”) by and between Sunesis and Biogen Idec MA Inc. (“Biogen Idec”), as amended prior to the Effective Date (the “Original Agreement”), Sunesis and Biogen Idec collaborated on the discovery and development of
small molecules that modulated Collaboration Targets (as defined in the Original Agreement), and discovered and commenced development of several compounds, including compounds designated as BIIB024 and [ * ] (each a “Licensed
Compound”, as further defined below), it being understood that BIIB024 has been designated as a “Development Candidate” under the terms of the Original Agreement. 

C. Pursuant to a Termination and Transition Agreement dated as of the Effective Date (the “Three Party Agreement”), Sunesis,
Biogen Idec and Millennium have agreed that (i) Millennium shall succeed to the rights of Biogen Idec under the Original Agreement with respect to the Licensed Compounds and, in order to effectuate the foregoing, (ii) Sunesis and
Millennium shall enter into this Agreement, Sunesis and Biogen Idec shall enter into an amendment and restatement of the Original Agreement (the “New Sunesis-Biogen Agreement”), and Millennium and Biogen Idec shall enter into an asset
transfer agreement (the “Millennium-Biogen Agreement”). 
 NOW, THEREFORE, for and in consideration of the covenants,
conditions and undertakings hereinafter set forth, it is agreed by and between the Parties as follows: 
 ARTICLE 1

 DEFINITIONS 
 As used herein, the following terms will have the meanings set forth below: 
 1.1.
“Affiliate” of a Person shall mean any corporation or other business entity that during the Term of this Agreement controls, is controlled by or is under common control with such Person but only for so long as such entity controls,
is controlled by, or is under common control with such Person. With respect to a particular entity, “control” shall mean the ownership 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
directly or indirectly of fifty percent (50%) or more of the stock entitled to vote for the election of directors, and for nonstock organizations, of the equity interests entitled to control
the management of such entity. [ * ]. 
 1.2. “Biogen Idec Collaboration Technology” shall mean all
Biogen Idec Collaboration Patents and Biogen Idec Collaboration Know-How. 
 1.2.1 “Biogen Idec Collaboration
Patents” shall mean (a) those Patent Rights set forth on Exhibit 1.4, the subject of which is an invention: (i) conceived in the course of performing the Research Program during the Research Term and reduced to practice
prior to the Effective Date solely by or under authority of personnel of Biogen Idec or any of its controlled Affiliates; or (ii) conceived and reduced to practice solely by or under authority of personnel of Biogen Idec or any of its
controlled Affiliates after the Original Agreement Effective Date but prior to the Effective Date, in the case of either (i) or (ii) in the course of activities [ * ] to the Designated Targets or to the discovery, research, or
development of Licensed Compounds or Licensed Products; and (b) all Patent Rights that arise during the Term that claim or cover any Biogen Idec Collaboration Know-How. Notwithstanding the foregoing, Biogen Idec Collaboration Patents shall in
all cases exclude Sunesis Core Technology, Joint Sunesis-Biogen Collaboration Patents and Sunesis Collaboration Patents. 

1.2.2 “Biogen Idec Collaboration Know-How” shall mean any Know-How: (i) made or developed solely by or under
authority of personnel of Biogen Idec or any of its controlled Affiliates in the course of performing the Research Program during the Research Term; or (ii) made or developed solely by or under authority of personnel of Biogen Idec or any of
its controlled Affiliates after the Original Agreement Effective Date but prior to the Effective Date, in the case of either (i) or (ii) in the course of activities [ * ] to the Designated Targets or to the discovery, research, or
development of Licensed Compounds or Licensed Products. Notwithstanding the foregoing, Biogen Idec Collaboration Know-How shall in all cases exclude Sunesis Core Technology, Joint Sunesis-Biogen Collaboration Know-How and Excluded Compounds (as
defined in the Original Agreement). 
 1.3. “Co-Funding Option” shall mean the option of Sunesis to fund a
portion of the post-Phase I Development Costs of a Licensed Product in the Co-Funded Territory as provided in Section 2.2. The “Co-Funded Territory” shall have the meaning set forth in Section 2.2.1. 

1.4. “Collaboration Technology” shall mean all Collaboration Patents and Collaboration Know-How. 

1.4.1 “Collaboration Patents” shall mean all Biogen Idec Collaboration Patents, Sunesis Collaboration Patents and Joint
Sunesis-Biogen Collaboration Patents. Exhibit 1.4 sets forth the Collaboration Patents existing as of the Effective Date. 
 1.4.2 “Collaboration Know-How” shall mean all Biogen Idec Collaboration Know-How, Sunesis Collaboration Know-How and Joint Sunesis-Biogen Collaboration Know-How. 

  
 -2-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 1.5. “Combination Product” shall mean any of (i) a Licensed
Product that incorporates two or more active drug substances including a Licensed Compound, or (ii) a Reverted Licensed Product that incorporates two or more active drug substances including a Reverted Compound; in each case where at least one
of the active drug substances is neither a Licensed Compound nor a Reverted Compound (respectively). 
 1.6.
“Commercially Reasonable and Diligent Efforts” shall mean the level of effort and resources normally used by a Party for a product or compound owned or controlled by it, which is of similar market potential and at a similar stage in
its development or product life, taking into account, without limitation, with respect to a product issues of safety and efficacy, product profile, the proprietary position of the product, the then current competitive environment for the product and
the likely timing of the product’s entry into the market, the regulatory environment of the product, and other relevant scientific, technical and commercial factors. Notwithstanding the foregoing, to the extent that the performance of a
Party’s responsibilities hereunder is adversely affected by the other Party’s failure to perform its responsibilities hereunder, such Party shall not be deemed to have failed to use its Commercially Reasonable and Diligent Efforts in
performing such responsibilities. Notwithstanding, but not in limitation of the foregoing, Millennium shall be deemed to be using Commercially Reasonable and Diligent Efforts for a Co-Funded Product specifically directed at a particular Designated
Target if it is using Commercially Reasonable and Diligent Efforts with respect to a Licensed Compound specifically directed at such Designated Target. 
 1.7. “Confidential Information” shall mean, with respect to a Party, all information (and all tangible and intangible embodiments thereof), which is owned or controlled by such Party, and
is disclosed by such Party to the other Party pursuant to this Agreement. Notwithstanding the foregoing, Confidential Information of a Party shall not include information which, and only to the extent, the receiving Party can establish by written
documentation (a) has been generally known prior to disclosure of such information by the disclosing Party to the receiving Party; (b) has become generally known, without the fault of the receiving Party, subsequent to disclosure of such
information by the disclosing Party to the receiving Party; (c) has been received by the receiving Party at any time from a source, other than the disclosing Party, rightfully having possession of and the right to disclose such information free
of confidentiality obligations; (d) has been otherwise known by the receiving Party free of confidentiality obligations prior to disclosure of such information by the disclosing Party to the receiving Party; or (e) is independently
developed without reference to or use of the Confidential Information of the disclosing Party. For clarity, except as otherwise expressly provided in this Agreement, Sunesis Collaboration Technology and Joint Sunesis-Biogen Collaboration Technology
shall be deemed Confidential Information of both Millennium and Sunesis. For clarity, Biogen Idec Collaboration Technology and Development Technology shall be deemed Confidential Information solely of Millennium. 

1.8. “Control” or “Controlled” shall mean, with respect to any Patent Rights or Know-how and with
respect to any Person, possession (whether by ownership or license, other than a license granted pursuant to this Agreement) by such Person or its Affiliate of the ability to grant 

  
 -3-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
the licenses or sublicenses as provided for herein without violating the terms of any agreement or other arrangement with any Third Party. 

1.9. “Covered” shall mean, with respect to a compound and a Valid Claim, that the manufacture, use, sale, offer for sale
or importation of such compound, but for the licenses or ownership rights granted herein, would infringe such Valid Claim. 

1.10. “Designated Targets” shall mean (i) the Raf Target and (ii) the [ * ] Target. 

1.11. “Development” shall mean all research, development and regulatory activities regarding the Licensed Products.
“Development” shall include all activities related to research, optimization and design of the appropriate molecule and identification of back-ups, preclinical testing, test method development and stability testing, toxicology,
formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality control, clinical studies, manufacturing clinical supplies, regulatory affairs, statistical analysis and report writing, technology
transfer, market research and development, and all other pre-approval and related post-approval activities. When used as a verb, “Develop” shall mean to engage in Development. 

1.12. “Development Candidate” shall mean any Licensed Compound that enters into GLP clinical toxicology testing or GMP
manufacturing. 
 1.13. “Development Costs” shall mean the costs and expenses associated with Development
activities actually incurred by Millennium or its Affiliates for a particular Licensed Product during the measurement period and in the territories described in Section 2.2.4(c). The costs and expenses associated with Development activities
shall include [ * ] In determining “Development Costs” chargeable under this Agreement, Millennium will use its project accounting systems, and will review its project accounting systems and methodologies with Sunesis. The Parties
hereby agree that efforts of the employees of Millennium or its Affiliates in performing its activities hereunder shall be charged as Development Costs at the FTE Rate. Notwithstanding anything in this Section 1.13 to the contrary, only those
Development Costs that are contemplated by the Co-Development Plan and Budget or were otherwise approved by the JSC shall be chargeable by Millennium as Development Costs. It is further understood that the activities of the following groups or
functions shall not be chargeable as Development Costs: [ * ]. All payments made by Millennium to a Third Party in connection with the performance of its activities under the Co-Development Plan and Budget shall be charged as Development
Costs at Millennium’s actual out-of-pocket cost. Expenses incurred by Millennium for equipment, materials and supplies utilized in performing its activities under the Co-Development Plan and Budget shall not be separately charged as Development
Costs, except for those expenses incurred by Millennium, with the prior written consent of the JSC as set forth in the Co-Development Plan and Budget, in the purchase or making of [ * ], and the like) that are to be used exclusively in
connection with the performance of Millennium’s activities under the Co-Development Plan and Budget (e.g., [ * ] etc.), which expenses shall be charged as Developments Cost at Millennium’s actual out-of-pocket expense incurred in
purchasing or making such [ * ]. 

  
 -4-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 1.14. “Development Technology” shall mean any Know-How that is made or
developed after the Effective Date and during the Term solely by or under authority of either Party or its Affiliates, or jointly by or under authority of both Parties or their respective Affiliates, in the course of performing any activity under
this Agreement [ * ] to a Designated Target or [ * ] to the Development, manufacturing or commercialization of a Licensed Compound or Licensed Product, and all Patent Rights that arise during the Term that claim or cover any such
Know-How. Notwithstanding the foregoing, Development Technology shall in all cases exclude Biogen Idec Collaboration Patents, Biogen Idec Collaboration Know-How, Sunesis Collaboration Technology, Sunesis Core Technology, Joint Sunesis-Biogen
Collaboration Patents and Joint Sunesis-Biogen Collaboration Know-How. 
 1.15. “Diligence Summary” shall mean,
with respect to a particular Product, a summary of Development and commercialization activities with respect to such Product, that (i) were performed by the reporting Party or its Third Party collaborators in the previous [ * ] period
(or shorter period from the prior Diligence Summary, if applicable), and (ii) as of the date of the Diligence Summary, are planned in good faith for the following [ * ] period. For clarity, it is understood and acknowledged that in
providing a Diligence Summary, a Party shall not be required to disclose scientific results, specific research activities or the identity of any Third Party collaborator or potential collaborator, but shall at a minimum provide a summary of the
total number of FTEs dedicated or planned to be dedicated to the Development and commercialization of such Product, and a summary of the functional allocation of such FTEs. 
 1.16. “Field” shall mean the treatment, prevention or diagnosis of disease in humans and animals. 
 1.17. “FTE” shall mean, with respect to a Party, the equivalent of the work time of a full-time clinician, regulatory or other qualified person over a twelve-month period (including
normal vacations, sick days and holidays), equal to at least [ * ] ([ * ]) weeks of work. In the case of less than a full-time person, the portion of an FTE year devoted by such person to Development activities shall be determined by
dividing the number of days during any twelve-month period devoted by such person to Development activities by the total number of working days of such person during such twelve-month period. “FTE Rate” for Millennium shall mean $[ *
] per annum per FTE from the Effective Date through December 31, 2011. Thereafter, the FTE Rate will be adjusted by the Inflation Index. As used herein, “Inflation Index” shall mean the percentage increase in the Consumer Price
Index for all Urban Consumers, as published by the U.S. Department of Labor, Bureau of Statistics, since the Effective Date. For clarity, the FTE rate for sales representatives involved in co-promotion shall be determined in accordance with
Section 3.2.3. 
 1.18. “Governmental Authority” shall mean any multi-national, federal, state, local,
municipal or other government authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). 

  
 -5-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 1.19. “Gross Sales” shall mean the gross amount invoiced by either
Party or its Affiliates or permitted Sublicensees for sales of a Product. However, Gross Sales shall not include amounts received by such Party (or any of its Affiliates) from transactions with an Affiliate or Sublicensee, where the Product in
question will be resold by such Affiliate or Sublicensee to an independent Third Party distributor, agent or end user and such amounts received by the Affiliate or Sublicensee from such resale is included in Gross Sales. 

1.20. “Joint Sunesis-Biogen Collaboration Technology” shall mean all Joint Sunesis-Biogen Collaboration Patents and
Joint Sunesis-Biogen Collaboration Know-How. 
 1.20.1 “Joint Sunesis-Biogen Collaboration Patents” shall mean
(a) those Patent Rights set forth on Exhibit 1.4, the subject of which is an invention: (i) conceived in the course of performing the Research Program during the Research Term and reduced to practice prior to the Effective Date
jointly by, or under authority of, both Sunesis and Biogen Idec; (ii) conceived and reduced to practice jointly by, or under authority of, Sunesis and Biogen Idec after the Original Agreement Effective Date but prior to the Effective Date, in
the case of either (i) or (ii) in the course of activities [ * ] to the Designated Targets or to the discovery, research, or development of Licensed Compounds or Licensed Products; or (iii) conceived in the course of performing
the Research Program during the Research Term and reduced to practice prior to the Effective Date using Joint Sunesis-Biogen Collaboration Know-How, Sunesis Collaboration Know-How or Sunesis Core Technology by or under authority of personnel of
Biogen Idec or any of its controlled Affiliates; and (b) all Patent Rights that arise during the Term that claim or cover any Joint Sunesis-Biogen Collaboration Know-How. For clarity, the inventions described in subsection (a)(iii) above are
limited to those inventions [ * ] or comprising compositions of matter that modulate Designated Targets or methods of use thereof in modulating Designated Targets. Notwithstanding the foregoing, Joint Sunesis-Biogen Collaboration Patents
shall in all cases exclude Sunesis Core Technology, Biogen Idec Collaboration Patents and Sunesis Collaboration Patents. 

1.20.2 “Joint Sunesis-Biogen Collaboration Know-How” shall mean any Know-How: (i) made or developed jointly by, or
under authority of, both Sunesis and Biogen Idec in the course of performing the Research Program during the Research Term; (ii) made or developed jointly by, or under authority of, both Sunesis and Biogen Idec after the Original Agreement
Effective Date but prior to the Effective Date, in the case of either (i) or (ii) in the course of activities [ * ] to the Designated Targets or to the discovery, research, or development of Licensed Compounds or Licensed Products.

 1.21. “Know-How” shall mean any data, inventions, invention disclosures, methods, proprietary information,
processes, techniques, technology, or material (including biological or other materials). 
 1.22. “Licensed
Compounds” shall mean (i) BIIB024, (ii) [ * ], (iii) the other compounds set forth on Exhibit F or Exhibit G of the Millennium-Biogen Agreement, (iv) all other compounds that were Synthesized in the
course of performing the Research Program during the Research Term in connection with activities relating to a Designated Target, (v) all 

  
 -6-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
other compounds claimed or covered by a Collaboration Patent, (vi) all other compounds claimed or covered by an invention disclosure within the Collaboration Know-How, (vii) all
compounds Synthesized [ * ] period following the Effective Date by or on behalf of Millennium in the course of activities directed to the [ * ] Target and through use of the Sunesis Licensed Technology, and (viii) all salts,
prodrugs, esters, metabolites, solvates, stereoisomers and polymorphs of any of the foregoing. 
 1.23. “Licensed
Product” shall mean a pharmaceutical preparation for sale by prescription, over-the-counter, or any other method for all uses in humans or animals, which incorporates one or more Licensed Compounds as an active drug substance, but excluding
Reverted Licensed Products. It is understood that Licensed Products containing different active ingredient(s) (i.e., a different active ingredient or an additional active ingredient) or a different formulation shall be deemed different
“Licensed Products”. 
 1.24. “NDA” shall mean a New Drug Application (or its equivalent), as defined
in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any corresponding or similar application, registration or certification in any jurisdiction for marketing authorization of a Product. 

1.25. “Net Sales” shall mean, with respect to a Product, Gross Sales less applicable Sales Returns and Allowances.

 If a sale, transfer or other disposition with respect to a Product is made for consideration other than cash or is not at
arm’s length, then the Net Sales from such sale, transfer or other disposition shall be the arm’s length fair market value thereof. For purposes of this Agreement, “sale” shall mean any transfer or other distribution or
disposition, but shall not include transfers or other distributions or dispositions of Product, at no charge, for pre-clinical, clinical or regulatory purposes or in connection with patient assistance programs or other charitable purposes or to
physicians or hospitals for promotional purposes. 
 In the event that a Product is sold in the form of a Combination Product,
Net Sales for the Product shall be determined by multiplying actual Net Sales of the Combination Product (determined by reference to the definition of Net Sales set forth above) during the royalty payment period by the fraction A/(A+B) where A
is the average sale price of the Product as the sole active drug substance when sold separately in finished form, and B is the average sales price of products containing only the other active ingredients when sold separately in finished form, in
each case during the applicable royalty payment period in the country in which the sale of the Combination Product was made, or if sales of both types of products did not occur in such period, then in the most recent royalty payment period in which
sales of both occurred. Where the Product is sold separately in finished form but the other ingredients are not, Net Sales for the Product shall be determined by multiplying actual Net Sales of the Combination Product (determined by reference to the
definition of Net Sales set forth above) during the royalty payment period by the ratio of the average per-unit sale price of the Product when sold separately in finished form to the average per-unit Net Sales of the Combination Product, in each
case during the applicable royalty payment period in the country in which the sale of the Combination 

  
 -7-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
Product was made. Where the other active ingredients are sold separately in finished form but the Product is not, Net Sales for the Product shall be determined by multiplying actual Net Sales of
the Combination Product (determined by reference to the definition of Net Sales set forth above) during the royalty payment period by the difference obtained by subtracting from one (1) the ratio of the average per-unit sale price of products
containing only the other active ingredient when sold separately in finished form to the average per-unit Net Sales of the Combination Product, in each case during the applicable royalty reporting period in the country in which the sale of the
Combination Product was made. In the event that such average sales price cannot be determined for either of the Product or for products containing only the other active ingredient included in the Combination Product, Net Sales for purposes of
determining payments under this Agreement shall be determined by good faith negotiations between the Parties. 
 1.26.
“Patent Rights” shall mean all patents and patent applications in any country in the world, including any continuations, continuations-in-part, divisionals, provisionals or any substitute applications, any patent issued with respect
to any such patent applications, any reissue, reexamination, renewal or extension (including any supplemental protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such
patent, and all non-United States counterparts of any of the foregoing. 
 1.27. “[ * ] Target” shall
mean human [ * ]. 
 1.28. “Person” shall mean any natural person, corporation, general partnership,
limited partnership, joint venture, proprietorship or other business organization or a Governmental Authority. 
 1.29.
“Phase I” shall mean human clinical trials, the principal purpose of which is the preliminary evaluation of safety in healthy individuals as more fully defined in 21 C.F.R. §312.21(a) or similar clinical study in a country
other than the United States. An initial study in patients where the primary purpose is the preliminary evaluation of safety will be considered a Phase I study. 
 1.30. “Phase II” shall mean human clinical trials conducted on a limited number of patients for the primary purpose of evaluation of both clinical efficacy and safety, or to obtain a
preliminary evaluation of the dosage regimen, as more fully defined in 21 C.F.R. §312.21(b). 
 1.31.
“Phase III” shall mean human clinical trials, the principal purpose of which is to establish substantial evidence of both safety and efficacy in patients with the disease or condition being studied, as more fully defined in 21
C.F.R. §312.21(c) or similar clinical study in a country other than the United States. Phase III shall also include any other human clinical trial intended to serve as a pivotal trial to support the submission of an application for regulatory
approval. 
 1.32. “Product” shall mean a Licensed Product or Reverted Licensed Product, as applicable.

 1.33. “Raf Target” shall mean the human Raf protein together with the Raf protein family members [ *
]. 

  
 -8-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 1.34. “Regulatory Approval” shall mean approval of the health
regulatory agency in a country (FDA in the U.S. and comparable authority outside the U.S.) necessary for the marketing and sale of a product in the applicable country. As used herein, “Regulatory Approval” shall not include pricing or
reimbursement approval. 
 1.35. “Research Program” shall mean the activities undertaken by Sunesis and Biogen
Idec pursuant to the Original Agreement during the Research Term. 
 1.36. “Research Term” shall mean the
period of time beginning on the Original Agreement Effective Date and ending on June 30, 2008. 
 1.37. “Reverted
Compound” shall mean, with respect to a Reverted Licensed Product, any Licensed Compound included in such Reverted Licensed Product. 
 1.38. “Sales Returns and Allowances” shall mean, with respect to a specific Product, the sum of (a) and (b), where: (a) is a provision, determined by a Party under U.S. GAAP for
sales of such Product for (i) trade, cash and quantity discounts on such Product (other than price discounts granted at the time of invoicing and which are already included in the determination of Gross Sales), (ii) credits or allowances
given or made for rejection or return of, and for uncollectable amounts on, previously sold product or for rebates or retroactive price reductions (including Medicare, Medicaid and similar types of rebates and chargebacks), (iii) taxes, duties
or other governmental charges levied on or measured by the billing amount for such Product, as adjusted for rebates and refunds (excluding income and franchise taxes), (iv) charges for freight and insurance directly related to the distribution
of such Product, to the extent included in Gross Sales, and (v) credits for allowances given or made for wastage replacement, indigent patient and any other sales programs agreed to by the Parties for such Product; and (b) is a periodic
adjustment of the provision determined in (a) to reflect amounts actually incurred by a Party for items (i), (ii), (iii), (iv) and (v) in clause (a). 
 1.39. “Sublicensee” shall mean a Third Party expressly licensed by a Party or its Affiliate to make, use, import, offer for sale or sell a Product. The term “Sublicensee” shall
not include distributors (i.e., a Third Party who purchases Product from a Party for resale). 
 1.40. “Sunesis
Collaboration Technology” shall mean all Sunesis Collaboration Patents and Sunesis Collaboration Know-How. 
 1.40.1
“Sunesis Collaboration Patents” shall mean (a) those Patent Rights set forth on Exhibit 1.4, the subject of which is an invention: (i) conceived in the course of performing the Research Program during the Research
Term and reduced to practice prior to the Effective Date solely by or under authority of personnel of Sunesis or any of its controlled Affiliates or (ii) conceived and reduced to practice solely by or under authority of personnel of Sunesis or
any of its controlled Affiliates after the Original Agreement Effective Date but prior to the Effective Date, in the case of either (i) or (ii) in the course of activities [ * ] to the Designated Targets or to the discovery,
research, or development of Licensed Compounds or Licensed Products; and (b) all Patent Rights that arise during the Term that claim or cover any Sunesis Collaboration Know-How. Notwithstanding the foregoing, Sunesis Collaboration

  
 -9-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
Patents shall in all cases exclude Sunesis Core Technology and Joint Sunesis-Biogen Collaboration Patents. 
 1.40.2 “Sunesis Collaboration Know-How” shall mean any Know-How: (i) made or developed solely by or under authority of personnel of Sunesis or any of its controlled Affiliates in the
course of performing the Research Program during the Research Term; or (ii) made or developed solely by or under authority of personnel of Sunesis or any of its controlled Affiliates after the Original Agreement Effective Date but prior to the
Effective Date, in the case of either (i) or (ii) in the course of activities [ * ] to the Designated Targets or to the discovery, research, or development of Licensed Compounds or Licensed Products. Notwithstanding the foregoing,
Sunesis Collaboration Know-How shall in all cases exclude Sunesis Core Technology, Joint Sunesis-Biogen Collaboration Know-How and Excluded Compounds (as defined in the Original Agreement). 

1.41. “Sunesis Core Technology” shall mean all Patent Rights (all as listed on Exhibit 1.41) and all information,
materials and other subject matter, and improvements thereof, relating to (i) mutants or the use thereof in screening, (ii) the use of novel protein engineering techniques and their application in drug discovery, (iii) target-directed
fragment discovery and maturation to produce drug leads, including monophores, extenders and fragments and monophore, extender and fragment libraries for such purposes, or (iv) covalent tethering and techniques related thereto (e.g., NMR,
X-ray, mass spec. AUC, Biacore) and its use to discover fragments and test binding hypotheses of fragments and leads: (a) Controlled by Sunesis or its controlled Affiliates prior to the Original Agreement Effective Date or during the Research
Term; or (b) made by Biogen Idec in the course of activities directed to the discovery, research, or development of Licensed Compounds; provided, in the case of (b) that such item was made using or derived from Sunesis Core Technology.

 1.42. “Sunesis Licensed Technology” shall mean Sunesis Licensed Patents and Sunesis Licensed Know-How.

 1.42.1 “Sunesis Licensed Patents” shall mean (i) Sunesis’s interest in Collaboration Patents,
(ii) the Patent Rights Controlled by Sunesis as of the Effective Date that claim or cover the Designated Targets, Licensed Compounds or Licensed Products, and (iii) all Patent Rights that arise during the Term that claim or cover any
Know-How Controlled by Sunesis as of the Effective Date that relates to a Designated Target, Licensed Compound or Licensed Product. 
 1.42.2 “Sunesis Licensed Know-How” shall mean (i) Sunesis Collaboration Know-How, (ii) Sunesis’s interest in Joint Sunesis-Biogen Collaboration Know-How and Biogen Idec
Collaboration Know-How, and (iii) any Know-How Controlled by Sunesis as of the Effective Date that relates to a Designated Target, Licensed Compound or Licensed Product. 
 1.43. “Synthesize”, “Synthesis” or “Synthesized” shall mean, with respect to a chemical composition, the act of (i) first physical synthesis of such
chemical composition, or (ii) if such composition had previously been first actually synthesized, first physically establishing, in a 

  
 -10-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
relevant assay, that such composition is Target Selective against a specific Designated Target. For avoidance of doubt Synthesize shall not include chemical compositions synthesized in
vivo. 
 1.44. “Target Selective” shall mean, when used to describe a chemical compound with respect to a
specified Designated Target, that such compound exhibits [ * ] cell-based assay, and [ * ] (i) [ * ] enzyme assay [ * ] or (ii) [ * ]. For the purposes of the foregoing, the relevant cell-based and enzyme
assays shall be as specified in Exhibit 1.44, and the [ * ] in (ii) shall be measured in the same enzyme assay as (i). 
 1.45. “Third Party” shall mean any person or entity other than Sunesis and Millennium, and their respective Affiliates. 

1.46. “Valid Claim” shall mean [ * ] 
 1.47. Additional Terms. In addition to the foregoing, the following terms shall have the meaning defined in the corresponding Section below: 

 

							
	 Term
	 	 Section
 Defined
	 	 Term
	 	 Section
 Defined

	Agreement	 	Preamble	 	Key Subsidiary	 	2.2.4(a)
				
	Annual Net Sales	 	6.3.1	 	Liabilities	 	12.1
				
	Biogen Idec	 	Background	 	Licensed Compound Joint Technology	 	9.1.1(c)
				
	Change in Control	 	2.2.4(a)	 	Licensed Product Team	 	2.3
				
	Co-Development Plan and Budget	 	2.2.2	 	Millennium	 	Preamble
				
	Co-Funded Product	 	2.2.1	 	Millennium-Biogen Agreement	 	Background
				
	Co-Funded Territory	 	2.2.1	 	Millennium Competitor	 	2.2.4(b)
				
	Co-Funding Percentage	 	2.2.3	 	New Sunesis-Biogen Agreement	 	Background
				
	[ * ]	 	15.3	 	Notice Period	 	2.2.1
				
	Controlling Party	 	9.3.4	 	Original Agreement	 	Background
				
	Cooperating Party	 	9.3.4	 	Original Agreement Effective Date	 	Background
				
	Co-Promoted Licensed Product	 	3.2	 	Other Joint Technology	 	9.1.1(c)
				
	Co-Promotion Option	 	3.2	 	Other Millennium Technology	 	5.1.3

  
 -11-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

							
	 Term
	 	 Section
 Defined
	 	 Term
	 	 Section
 Defined

	Election Notice	 	2.2.1	 	Party, Parties	 	Preamble
				
	Election Percentage	 	3.2.1	 	Phase II Drug Collaboration	 	5.3
				
	Indemnitee	 	12.3	 	Phase II Notice	 	2.2.1
				
	Indemnitor	 	12.3	 	post Phase I Development Costs	 	2.2.4(c)
				
	Indication	 	6.2.2(b)	 	Projected Start Date	 	2.2.1
				
	Initial Development Plan	 	2.2.1	 	Raf Patents	 	9.1.1(a)
				
	Initial Territory	 	2.2	 	Reverted Licensed Product	 	8.2
				
	Infringement Action	 	9.3.4	 	Sales and Marketing Plan	 	4.4.2
				
	JCC	 	4.4.1	 	Sunesis	 	Preamble
				
	JDC	 	4.3.1	 	Subject Infringement	 	9.3.1
				
	Joint Steering Committee	 	4.1	 	Term	 	13.1
				
	Joint Sub-Committee	 	4.2	 	Three Party Agreement	 	Background

 1.48. Construction. In
construing this Agreement, unless expressly specified otherwise: 
 1.48.1 references to Sections, Articles and Exhibits are to
sections and articles of, and exhibits to, this Agreement; 
 1.48.2 except where the context otherwise requires, use of any
gender includes any other gender, and use of the singular includes the plural and vice versa; 
 1.48.3 any list or examples
following the word “including” shall be interpreted without limitation to the generality of the preceding words; 

1.48.4 except where the context otherwise requires, the word “or” is used in the inclusive sense; and 

1.48.5 all references to “dollars” or “$” herein shall mean U.S. Dollars. 

  
 -12-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 ARTICLE 2 
 PRODUCT DEVELOPMENT 
 2.1. Development by Millennium. Commencing on
the Effective Date, Millennium shall be responsible for undertaking a development program aimed at ultimately seeking Regulatory Approval for Licensed Products. 
 2.2. Co-Funding Option. Sunesis shall have the right, on a Licensed Product-by-Licensed Product basis, to elect to fund a portion of post Phase I Development Costs of a Licensed Product in all
countries worldwide other than Japan (the “Initial Territory”); provided, however, that Sunesis shall not have the Co-Funding Option with respect to any Licensed Product directed against a Designated Target for which Sunesis has entered
into a Phase II Drug Collaboration. In the event that Sunesis elects to exercise its Co-Funding Option with respect to the Initial Territory for a particular Licensed Product pursuant to the preceding sentence, then Sunesis shall have the right to
elect to fund a portion of post Phase I Development Costs of such Licensed Product in Japan, all in accordance with this Section 2.2. 
 2.2.1 Election. For so long as Sunesis continues to have a Co-Funding Option for a Licensed Product, Millennium shall notify Sunesis [ * ] for each Licensed Product in each of the applicable
territories described above in Section 2.2 where the primary endpoint of such trial involves a preliminary determination of efficacy. Such notice shall include the date [ * ] Sunesis may elect, by so notifying Millennium in writing [
* ] (the “Notice Period”), to participate in funding the further development of such Licensed Product in the applicable territory, as described in this Section 2.2 (such notice, the “Election Notice”). [ * ] until
the end of the Notice Period, Millennium shall cooperate fully with Sunesis, and shall promptly provide Sunesis with access to such material information, to the extent such information is not included in the Initial Development Plan or otherwise has
not been communicated previously to Sunesis, as Sunesis may reasonably request to enable Sunesis to make an informed decision whether to exercise its Co-Funding Option under this Section 2.2 with respect to such Licensed Product. Such
cooperation shall include consulting with Sunesis in good faith regarding the Initial Development Plan, and the financial, scientific and regulatory assumptions reflected therein. In the event Sunesis exercises its Co-Funding Option with respect to
a particular Licensed Product (such Licensed Product, a “Co-Funded Product”), the provisions of Sections 2.2.2 through 2.2.4 below shall apply with respect to such Co-Funded Product in the Co-Funded Territory. The “Co-Funded
Territory” shall consist of the Initial Territory for each Co-Funded Product, and in the event Sunesis elects to exercise its Co-Funding Option for Japan with respect to a particular Co-Funded Product, the Co-Funded Territory shall mean all
territories worldwide for such Co-Funded Product. In the event that Sunesis elects not to exercise the Co-Funding Option with respect to a Licensed Product or fails to provide an Election Notice within the applicable Notice Period, Sunesis shall no
longer have the right to exercise the Co-Funding Option, and Millennium shall have no further obligations under this Section 2.2.1, with respect to such Licensed Product. 
 2.2.2 JDC. For each Co-Funded Product, the Parties shall establish and maintain a JDC in accordance with Section 4.3 below, which shall be responsible for establishing

  
 -13-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
the plan and budget for the development of each Co-Funded Product (each, a “Co-Development Plan and Budget”) and overseeing the implementation of such plan. Such Co-Development Plan and
Budget shall be comprehensive (as of the time of preparation and delivery hereunder) and shall fully describe at least the proposed activities and data related to [ * ], and other activities and timelines directed to obtaining the initial and
subsequent Regulatory Approvals in each applicable country. Unless otherwise specified in a Co-Development Plan and Budget amounts reflected for a full year shall be deemed budgeted in equal amounts for each calendar quarter of such year.

 2.2.3 Co-Funding Obligation. In the event Sunesis exercises its Co-Funding Option with respect to a Licensed Product,
Sunesis shall be obligated to reimburse Millennium for a percentage (the “Co-Funding Percentage”) of post Phase I Development Costs for such Licensed Product, subject to the provisions of this Section 2.2. It is understood and agreed
that the Co-Funding Percentage shall initially be [ * ] percent ([ * ]%) for each Co-Funded Product. In addition the following shall apply: 
 (a) The Co-Development Plan and Budget will be updated on a quarterly basis. Millennium shall provide to Sunesis its then current estimates for each upcoming budget year for each Co-Funded Product by
November 15 of each year. Promptly following April 1 of each calendar year during the development activities for a particular Co-Funded Product or such other date as is mutually agreed by the Parties, the JDC shall update and amend the
Co-Development Plan and Budget for such Co-Funded Product for the period ending March 31 of the subsequent calendar year. Millennium shall provide Sunesis with reasonable opportunity to provide input into each Co-Development Plan and Budget,
and, subject to Article 4, Millennium shall reasonably consider Sunesis’s comments in establishing and updating each Co-Development Plan and Budget. 
 (b) Within thirty (30) days after the end of each calendar quarter, Millennium shall provide to Sunesis a statement reflecting the total post Phase I Development Costs incurred by Millennium in
accordance with the then-current Co-Development Plan and Budget during such calendar quarter with respect to each Co-Funded Product. Within thirty (30) days after Sunesis’s receipt of such statement, Sunesis shall reimburse Millennium for
the applicable Co-Funding Percentage of the post Phase I Development Costs incurred by Millennium during such calendar quarter for such Co-Funded Product. 
 (c) Upon [ * ] days written notice to Millennium, Sunesis may terminate its Co-Funding Option for a particular Co-Funded Product. In such event, Sunesis’s funding obligation under this
Section 2.2.3 above shall apply only with respect to post Phase I Development Costs for activities conducted with respect to such Co-Funded Product prior to the effective date of such termination. Should Sunesis terminate its Co-Funding Option
under this Section 2.2.3(c) with respect to a particular Co-Funded Product, (i) any royalties payable to Sunesis on such Co-Funded Product shall be paid in accordance with Section 6.3.1, subject to Section 6.3.2(b), and
(ii) Sunesis shall relinquish its right to participate in the JDC pursuant to Section 4.3 and any right to its Co-Promotion Option under Section 3.2 for such Co-Funded Product. 

  
 -14-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 (d) Upon written notice to Millennium at least ninety (90) days prior to the end
of a budget year, Sunesis may elect to [ * ], by so notifying Millennium in writing, referencing this Section 2.2.3(d) and specifying [ * ]. In such event, Sunesis shall receive a [ * ] in accordance with the schedule set
forth in Section 6.3.2(c) below [ * ]. Upon such election, Sunesis’s previous Co-Funding Percentage under this Section 2.2.3 shall apply only with respect to post Phase I Development Costs for activities conducted with respect
to such Co-Funded Product [ * ] with respect to such Co-Funded Product. Sunesis may [ * ] provided that (i) Sunesis shall not be permitted [ * ] its Co-Funding Percentage for such Co-Funded Product, and (ii) Sunesis
may [ * ]. As used herein, “budget year” shall mean April 1 through March 31, provided that Millennium shall have the right to change the budget year to coincide with Millennium’s annual budget cycle, provided that
Millennium provides Sunesis with at least one hundred twenty (120) days notice of such change. 
 (e) Notwithstanding the
foregoing, in the event that Sunesis experiences a Change in Control, then Sunesis’s Co-Promotion rights under Section 3.2, the right to participate in the JDC under Section 4.3, the right to participate in the JCC under
Section 4.4, and any Licensed Product Teams under Section 2.3 shall terminate. In addition: 
 (i) With respect to
any Co-Funded Product for which Sunesis has exercised its Co-Funding Option prior to such Change of Control, Sunesis’s rights and obligations under this Section 2.2.3 shall continue, provided that Millennium shall no longer be obligated to
provide the detailed plans required of a Co-Development Plan and Budget to Sunesis (or its successor entity), but shall provide Sunesis (or its successor entity) with annual budgets of post Phase I Development Costs for such Co-Funded Product.

 (ii) Sunesis’s Co-Funding Option with respect to future Licensed Products shall continue as well (i.e., with respect to
Licensed Products that are not Co-Funded Products as of the date of such Change of Control), provided that Millennium shall no longer be obligated to provide for each Licensed Product the detailed plans and clinical data required of an Initial
Development Plan and Phase II Notice. Millennium shall, however, provide Sunesis (or its successor entity) with annual budgets of post Phase I Development Costs for such Co-Funded Product in accordance with the timetable for a Phase II Notice set
forth in Section 2.2.1, and shall provide reasonable cooperation to Sunesis (or its successor entity) in evaluating such Licensed Product and the post Phase I Development Costs related thereto, including consulting with Sunesis (or its
successor entity) in good faith regarding such annual budgets and the financial, scientific and regulatory assumptions reflected therein. 
 2.2.4 Certain Terms. As used in this Section 2.2, the following terms shall have the meanings set forth below: 
 (a) “Change in Control” shall mean, [ * ] 
 (b) “Millennium
Competitor” shall mean [ * ] 
 (c) “post Phase I Development Costs” shall mean, with respect to a
particular Co-Funded Product, the Development Costs incurred by Millennium or its Affiliates 

  
 -15-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
following Sunesis’s exercise of the Co-Funding Option for such Co-Funded Product in the Co-Funded Territory for such Co-Funded Product. For the avoidance of doubt, (i) post Phase I
Development Costs shall not include any Development Costs incurred by Millennium or its Affiliates for any subsequent Phase I trials, and (ii) Development Costs relating to activities directed at obtaining Regulatory Approval in Japan for a
Co-Funded Product shall not be considered post Phase I Development Costs to the extent such Development Costs are incurred (A) prior to completion of the Phase I trials for such Co-Funded Product in Japan, or (B) if no Phase I trials are
necessary or performed for such Co-Funded Product in Japan, then prior to initiation of any clinical trial other than a Phase I trial. 
 2.3. Licensed Product Team. Upon identification of a Development Candidate for any Licensed Compound other than BIIB024, the Parties shall form a product team with respect to such Licensed Compound
(which team shall report to the JDC if Sunesis exercises its Co-Funding Option with respect to such Licensed Compound), comprised of Millennium and Sunesis personnel, that will share all relevant information and implement the further development and
regulatory affairs with respect to that Co-Funded Product (each a “Licensed Product Team”) in accordance with the Co-Development Plan and Budget. It is understood that both Millennium and Sunesis shall have the opportunity for meaningful
participation in the activities of a Licensed Product Team commensurate with their respective levels of funding participation; it being further understood that Millennium shall control the Development of the Licensed Product. Sunesis shall be
notified at least two weeks in advance of the date of each Licensed Product Team meeting, which meetings shall be held quarterly by in-person meetings or electronic conference, and shall have the opportunity to have its representatives attend such
meeting. Millennium shall provide such Sunesis representatives with all information distributed to Millennium members of the Licensed Product Team, and such other material information as Sunesis may reasonably request from time to time. With respect
to [ * ], within thirty (30) days after the Effective Date, the Parties shall establish a Licensed Product Team for [ * ] as a Licensed Product (i.e., even though the such Licensed Product is not yet a Co-Funded Product). The
Parties shall maintain any such Licensed Product Team under this Section 2.3 until the Co-Funding Option lapses or is declined with respect to such Licensed Product. For clarity, it is understood that the establishment of a Licensed Product
Team hereunder for a Licensed Product directed at the Raf Target or the [ * ] Target shall not obligate Sunesis to subsequently exercise the Co-Funding Option with respect to such Licensed Product. The Licensed Product Team will be composed
of three (3) representatives of Millennium (at Millennium’s discretion) and three (3) representatives of Sunesis, who shall be appointed (and may be replaced at any time) by the respective Party on written notice to the other Party in
accordance with this Agreement. The Parties may invite additional employee observers based on the subject matter of the meeting, who shall be able to participate in such meetings. The Sunesis representatives shall not be entitled to vote on any
Licensed Product Team matters. In any event, the Licensed Product Team shall terminate in the event that Sunesis does not exercise its Co-Funding Option. 
 2.4. Regulatory Matters. Millennium shall file and be the owner of all regulatory filings for Licensed Compounds or Licensed Products (including Co-Funded Products) developed pursuant to this
Agreement, including all NDAs and Regulatory Approvals, unless otherwise agreed by the Parties. 

  
 -16-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 2.5. Records; Inspections. 

2.5.1 Research Records. Sunesis shall maintain records of the Research Program relating to the Licensed Compounds and Designated
Targets (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved in such performance of the Research Program. 

2.5.2 Inspections. During the one-year period following the Effective Date, Sunesis shall provide Millennium with access to the
records referred to in Section 2.5.1, upon reasonable request, during ordinary business hours and subject to appropriate confidentiality agreement in the event that Third Party confidential information is involved. 

ARTICLE 3 

PRODUCT COMMERCIALIZATION 
 3.1. Commercialization Rights. Subject to the provisions of Section 3.2, Millennium shall be responsible for the establishment and implementation of the strategy, plans and budgets for
marketing and promotion of the Licensed Products. 
 3.2. Co-Promotion Option. Sunesis will have an option (the
“Co-Promotion Option”) to co-promote each Co-Funded Product in the Co-Funding Territory, according to the terms and conditions set forth in this Section 3.2. This Co-Promotion Option may be exercised at Sunesis’s discretion on a
Co-Funded Product-by-Co-Funded Product and country-by-country basis for any Co-Funded Product, by so notifying Millennium in writing within [ * ] for such Co-Funded Product in such country (each such Co-Funded Product for which Sunesis
exercises the Co-Promotion Option being referred to as a “Co-Promoted Licensed Product”). [ * ] Millennium shall provide Sunesis with a good faith estimate of the number of field force personnel to be deployed for such Co-Funded
Product in the applicable territory for [ * ], together with a then-current Sales and Marketing Plan for such Co-Funded Product. The estimate of the number of field force personnel to be deployed shall be prepared by the JCC, and shall take
into consideration the then-current marketing and promotion practices in the relevant markets and the number and nature of other products, if any, including the detail position, if applicable, that such field force personnel will be selling. In
situations where field force personnel will be selling multiple products, the JCC shall make a good faith allocation of the field force personnel’s time to be spent on each product. In the event that Sunesis elects not to exercise the
Co-Promotion Option with respect to a Co-Funded Product or fails to notify Millennium in writing of its election within the applicable [ * ] in any country, Sunesis shall no longer have the right to exercise the Co-Promotion Option with
respect to such Co-Funded Product in such country. 
 As used in this Agreement, “co-promote” or
“co-promotion” shall mean to promote jointly or joint promotion of a Licensed Product through Millennium’s and Sunesis’s respective sales forces under the same brand name, with Millennium booking all sales of such Co-Promoted
Licensed Product, all as shall be more specifically set forth in a co-promotion agreement for each of the countries in which Sunesis co-promotes, such agreement to be negotiated in good faith as soon as practicable following the exercise by Sunesis
of the Co-Promotion Option for a Co-Promoted Licensed Product and reflecting the terms set forth in this Article 3 and other 

  
 -17-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
customary terms and provisions. A co-promotion agreement shall include the following provisions: (a) Sunesis shall, within thirty (30) days of the end of each calendar quarter, send a
written report to Millennium setting out for each applicable country and each Co-Promoted Licensed Product, the number of field sales force representatives performing co-promotion activities hereunder, and the number and nature of other products, if
any, that such field force personnel promoted during such calendar quarter. (b) In the event that [ * ] that are allocated to Sunesis in the applicable Sales and Marketing Plan, Millennium may terminate Sunesis’s right to co-promote
such Co-Promoted Licensed Product in such country upon written notice to Sunesis. 
 3.2.1 Scope and Coordination of
Co-Promotion. Upon exercise of its Co-Promotion Option with respect to a Co-Promoted Licensed Product, Sunesis shall have the right to field [ * ] (the “Election Percentage”) of the field force efforts, as such field force is
determined in good faith by the JCC, with respect to the Co-Promoted Licensed Product in the applicable country. The JCC shall be responsible for coordinating the co-promotion activities under this Section 3.2, and shall develop the strategies
and programs to optimally carry out marketing and promotional activities, including the assignment of sales force responsibilities in accordance with the Sales and Marketing Plan. It is understood that Sunesis may use one or more contract service
organizations for its activities under this Section 3.2, provided that with respect to each Co-Promoted Licensed Product, Sunesis [ * ] for such Co-Promoted Licensed Product. Sunesis field sales force representatives will be employed by
Sunesis and Sunesis shall be responsible for the payment of all such representatives’ salary, out-of pocket expenses (other than for promotional materials), bonus (Sunesis shall adopt reasonable bonus plans/systems to reward sales of the
Co-Promoted Licensed Product) and benefits, pension, insurance, social security and any other related obligations. 
 3.2.2
Co-Promotion Obligations. Sunesis shall employ a professional and trained sales force to co-promote the Co-Promoted Licensed Product, and such sales force shall meet standards of competence and professionalism as are common in the
pharmaceutical industry. In all events, Sunesis’s co-promotion shall be conducted as directed by the JCC and in accordance with the then current Sales and Marketing Plan and in accordance with all applicable laws. Millennium shall provide to
Sunesis’s sales personnel [ * ] any Co-Promoted Licensed Product-specific training and promotional materials (including samples), and shall permit Sunesis’s sales personnel to attend and participate in any Co-Promoted Licensed
Product-specific seminars and sales training programs [ * ] Sunesis, in each case as reasonably necessary to effectively promote the particular Co-Promoted Licensed Product consistent with the Sales and Marketing Plan. 

3.2.3 Reimbursement. For the performance of the obligations of Sunesis under this Section 3.2 and the co-promotion agreement,
Millennium shall reimburse Sunesis as described herein. [ * ]. In the event that Sunesis sales representatives promote any other products other than such Co-Promoted Licensed Product, then Millennium shall only reimburse Sunesis for the pro
rata share of the cost of such Sunesis sales representatives. 
 3.2.4 Right to Terminate Co-Promotion. Sunesis shall
have the right, on a territory-by-territory basis, to terminate its co-promotion of any Co-Promoted Licensed Product, 

  
 -18-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
and its obligations under this Section 3.2 with respect to such Co-Promoted Licensed Product, on a Co-Promoted Licensed Product-by-Co-Promoted Licensed Product basis, upon [ * ] prior
written notice to Millennium. Millennium shall have the right, on a country-by-country basis, to terminate Sunesis’s co-promotion of any Co-Promoted Licensed Product, and Millennium’s obligations under this Section 3.2 with respect to
such Co-Promoted Licensed Product, on a Co-Promoted Licensed Product-by-Co-Promoted Licensed Product basis, (a) [ * ] after written notice to Sunesis following any material breach of any applicable law, rule or regulation with respect to
the co-promotion of such Co-Promoted Licensed Product, or (b) [ * ] after written notice to Sunesis following any other material breach by Sunesis relating to the co-promotion of such Co-Promoted Licensed Product in such country if
Sunesis does not cure such breach within the applicable specified cure period in Section 3.2.4(a) or (b). Upon termination of co-promotion under this Section 3.2.4 or the co-promotion agreement, Sunesis shall have no right to reimbursement
by Millennium under Section 3.2.3 for services provided in the applicable country after the effective date of such termination. 
 3.3. Amendment of Sales and Marketing Plan. Promptly upon exercise of Sunesis’s Co-Promotion Option hereunder, the JCC shall meet to revise the Sales and Marketing Plan to reflect the sales
activities to be undertaken by Sunesis, including the formulation of a mechanism to establish and adjust cost allocation, and the definition of a relevant field sales force promotional activity metric for purposes of allocating the activities of
sales representatives. 
 3.4. Sunesis [ * ]. To the extent consistent with applicable law, the [ * ]
Sunesis shall [ * ], on all [ * ] for all [ * ] Licensed Products in the applicable country. 
 3.5.
Sunesis Insurance. In the event that Sunesis exercises its Co-Promotion Option, Sunesis shall procure and continue to maintain, at its own cost, the following insurance coverage: Commercial General Liability, including coverage for products
and completed operations (maintained for a period of at least five (5) years after expiration or termination of this Agreement) and contractual liability (including coverage for advertising and personal injury). The JCC shall set commercially
reasonable and appropriate minimum terms and conditions for such insurance coverage, consistent with then-current pharmaceutical industry practice for commercialization efforts of similar scope to the co-promotion activities undertaken hereunder.
Sunesis shall provide Millennium with a certificate of insurance reflecting such coverage. 
 ARTICLE 4 

MANAGEMENT 

4.1. Joint Steering Committee. Within thirty (30) days of the Effective Date, the Parties shall establish a joint steering
committee (“Joint Steering Committee”) to provide oversight and management of the activities undertaken under this Agreement. The Joint Steering Committee will be composed of two (2) representatives of each Party who shall be
appointed (and may be replaced at any time) by such Party on prior written notice to the other Party in accordance with this Agreement. At least one (1) representative of a Party on the Joint Steering Committee shall be a vice president or more
senior officer of such Party, and the representatives 

  
 -19-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
shall have relevant experience and expertise in research, development and commercialization of biopharmaceuticals. 
 4.1.1 Responsibilities. The Joint Steering Committee shall be responsible for (i) reviewing the efforts of the JDC in the conduct of ongoing development activities and regulatory affairs with
respect to Co-Funded Products under Article 2, and resolving disputes as to matters to be decided by the JDC under this Agreement; (ii) reviewing the efforts of the JCC in the conduct of promotional activities of the Parties with respect to
Co-Promoted Licensed Products under Article 3, and resolving disputes as to matters to be decided by the JCC under this Agreement; and (iii) taking such other actions as are specifically allocated to the Joint Steering Committee under this
Agreement. 
 4.1.2 Meetings. The Joint Steering Committee shall meet quarterly, or at such frequency as agreed by the
respective committee members. Meetings of the Joint Steering Committee shall be at such locations as the Parties agree, and will otherwise communicate regularly by telephone, electronic mail, facsimile or video conference. With the consent of the
Parties, other representatives of Sunesis or Millennium may attend the Joint Steering Committee meetings as nonvoting observers based on the subject matter of the meeting. 
 4.1.3 Decisions. Any approval, determination or other action of the Joint Steering Committee shall require agreement of the members of the Joint Steering Committee, with each Party having one
(1) vote. Action that may be taken at a meeting of the Joint Steering Committee also may be taken without a meeting if a written consent setting forth the action so taken is signed by all members of the Joint Steering Committee. 

4.1.4 Disputes. In the event the Joint Steering Committee is unable to reach consensus on a particular matter within its
jurisdiction or that of the JDC or JCC, the matter shall be referred to executives of the Parties in accordance with Section 14.1, and if such referral does not resolve such matter, then Millennium shall have the right to cast a deciding vote
on the JSC. Notwithstanding the foregoing, Millennium shall not have the right to exercise [ * ] of this Agreement or that [ * ] Sunesis. In the evaluation of a Diligence Summary pursuant to Section 8.5, any decision of the JSC
shall be binding on the Parties, but in the event the JSC is unable achieve agreement with respect to such evaluation, then such dispute shall be resolved as set forth in Section 8.5. 

4.2. Joint Sub-Committees. The Parties shall form the JDC and JCC (each, a “Joint Sub-Committee”) in accordance with the
terms set forth in Sections 4.3 and 4.4. 
 4.2.1 Generally. Each Joint Sub-Committee shall meet at such locations as the
Parties agree, and will otherwise communicate regularly by telephone, electronic mail, facsimile or video conference. Each Party shall be responsible for all of its own expenses associated with attendance of such meetings, and either Party may
replace its respective representatives to each Joint Sub-Committee at any time, with prior written notice to the other Party. Other representatives of Sunesis or Millennium may attend the Joint Sub-Committee meetings as nonvoting observers based on
the subject matter of the meeting. From time to time, each Joint 

  
 -20-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
Sub-Committee may establish further subcommittees to oversee particular projects or activities, and such further subcommittees will be constituted as such Joint Sub-Committee approves.

 4.2.2 Decision Making. Decisions of each Joint Sub-Committee shall be made by unanimous approval of the team leaders
from each Party present in person or by other means (e.g., teleconference) at any meeting; provided that at least one member from each Party must be so present and voting. In the event that unanimity is not achieved within a Joint Sub-Committee on a
decision required to be made by such Joint Sub-Committee, the matter will be referred to the Joint Steering Committee, which in each case shall promptly meet and endeavor in good faith to resolve such matter in a timely manner. In the event the
Joint Steering Committee is unable to reach consensus on a particular matter, such matter shall be resolved in accordance with Section 4.1.4 above. 
 4.3. Joint Development Committee. 
 4.3.1 Formation. Promptly
following notice from Sunesis that it is exercising its Co-Funding Option, the Parties shall establish a Joint Development Committee (“JDC”) with respect to the development of the applicable Co-Funded Product. The JDC will be composed of
three (3) representatives of Millennium (at Millennium’s discretion) and three (3) representative of Sunesis who shall be appointed (and may be replaced at any time) by the respective Party on written notice to the other Party in
accordance with this Agreement. In the event that Sunesis undergoes a Change of Control (as that term is defined in Section 2.2.4(a) above), the JDC shall be dissolved in accordance with Section 2.2.3(e). 

4.3.2 Responsibilities. The responsibilities of the JDC shall consist of (i) overseeing the ongoing development of Co-Funded
Product(s), (ii) establishing Co-Development Plans and Budgets for Co-Funded Products, (iii) monitoring and approving development activities under such Co-Development Plans and Budgets, (iv) reviewing and approving regulatory
correspondence, final study reports and submissions to Regulatory Authorities relating to Co-Funded Products, and (v) making such decisions as are expressly provided in Article 2. 

4.3.3 Meetings and Information. The JDC shall meet at least quarterly. Millennium shall notify Sunesis at least two weeks in
advance of the date of each JDC meeting. 
 4.4. Joint Commercialization Committee. 

4.4.1 Formation. Upon request by either Party following [ * ] for a Co-Funded Product and the election to co-promote by
Sunesis, the Parties shall establish a Joint Commercialization Committee (“JCC”) with respect to commercialization of such Co-Funded Product(s). The JCC will be composed of three (3) representatives of Millennium (at Millennium’s
discretion) and three (3) representative of Sunesis who shall be appointed (and may be replaced at any time) by the respective Party on written notice to the other Party in accordance with this Agreement. In any event, the JCC shall terminate
upon the expiration of all Co-Promotion Options or termination of all co-promotion by Sunesis. 

  
 -21-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 4.4.2 Responsibilities. The JCC shall have responsibility to monitor the conduct
and progress of the commercialization strategy, plans, and budgets, including establishment of a plan and budget for the marketing, promotion, sale and distribution of such Co-Funded Product (each a “Sales and Marketing Plan”) and managing
the promotional activities of the Parties with respect to Co-Promoted Licensed Products under Article 3 above. The JCC shall update the Sales and Marketing Plan periodically, and no less often than annually, and shall include therein detailed plans
and budgets for the marketing, promotion, sale and distribution of each Co-Funded Product. 
 4.4.3 Meetings and
Information. The JCC shall meet at least quarterly. Millennium shall notify Sunesis at least two weeks in advance of the date of each JCC meeting. 
 ARTICLE 5 
 LICENSES 

5.1. Development and Commercialization Licenses. 
 5.1.1 License under the Sunesis Licensed Technology to Licensed Products. Subject to the terms and conditions of this Agreement, Sunesis hereby grants to Millennium a worldwide, exclusive license
under the Sunesis Licensed Technology, with the right to grant and authorize sublicenses as provided in Section 5.2, to Develop, make, have made, use, import, offer for sale, sell and otherwise exploit Licensed Compounds and Licensed Products
in the Field. 
 5.1.2 License under the Sunesis Core Technology to Licensed Products. Subject to the terms and
conditions of this Agreement, Sunesis hereby grants to Millennium a worldwide, non-exclusive license under the Sunesis Core Technology to make, have made, use, import, offer for sale and sell Licensed Compounds and Licensed Products in the Field. It
is understood that the foregoing license to Sunesis Core Technology shall not include the right to practice Sunesis Core Technology to discover novel compositions. 
 5.1.3 License for Reverted Licensed Products. Subject to the terms and conditions of this Agreement (including Sections 5.1.1 and 5.1.2 above), with respect to each Reverted Licensed Product
Millennium hereby grants to Sunesis a worldwide, exclusive license under Millennium’s interest in the Biogen Idec Collaboration Technology, Joint Sunesis-Biogen Collaboration Technology, Development Technology and other Patent Rights and Know
How [ * ] the relevant Licensed Product becomes a Reverted Licensed Product (“Other Millennium Technology”), with the right to grant and authorize sublicenses as provided in Section 5.2, to develop, make, have made, use,
import, offer for sale, sell and otherwise exploit such Reverted Licensed Product. It is understood and acknowledged that the licenses granted with respect to Biogen Idec Collaboration Technology, Development Technology and Other Millennium
Technology in this Section 5.1.3 extend solely to that technology that is being used on that Reverted Licensed Product as of the date of such reversion to Sunesis, and solely to the extent necessary for Sunesis to continue development and
commercialization of such Reverted Licensed Product in the form in which such Reverted Licensed Product existed as of the date of such reversion to Sunesis. 

  
 -22-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 5.2. Grant of Sublicenses. Within a reasonable period of time following grant of
any sublicense, to the extent sublicensing is permitted under Section 5.1, the sublicensing Party shall provide the other Party with a summary of such sublicense, including the identity of the Sublicensee (including any Affiliate) and the
rights granted with respect thereto for each product and territory, sufficient to allow such other Party to verify any amounts then or subsequently due under Articles 6 and 7 below; provided that such summary may redact confidential information that
the sublicensing Party is reasonably prohibited from disclosing under the sublicense agreement. Any sublicense granted under this Section 5.2 shall be consistent with all of the terms and conditions of this Agreement, and subordinate thereto,
and the sublicensing Party shall remain responsible to the other Party for the compliance of each such Sublicensee with the obligations due under this Agreement. 
 5.3. Sunesis Covenant [ * ] Notwithstanding the foregoing, Sunesis shall not be prohibited from collaborating with a Third Party on the development and commercialization of chemical
compounds in-licensed from or controlled by such Third Party [ * ]; provided that Sunesis has not exercised the Co-Funding Option with respect to a Licensed Product [ * ] and such compounds are in Phase II clinical trials or later
stage of development or commercialization at the time of initiation of such collaboration (a “Phase II Drug Collaboration”). Sunesis shall notify Millennium in writing upon entering into a Phase II Drug Collaboration. Nothing in this
Section 5.3 is intended as the grant of a license by Millennium to Sunesis. 
 5.4. Assay License. Millennium hereby
grants to Sunesis a fully-paid, royalty-free worldwide, non-exclusive, perpetual, irrevocable license under Millennium’s rights in the assays set forth on Exhibit 1.44 for use by Sunesis solely to comply with Sunesis’s obligations
under this Agreement. 
 5.5. No Other Rights; No Implied Licenses. Only the licenses granted or retained pursuant to the
express terms of this Agreement shall be of any legal force or effect. No other license rights shall be created by implication, estoppel or otherwise. 
 ARTICLE 6 
 PAYMENTS 

6.1. Research Milestones. Millennium shall pay to Sunesis the following amounts within thirty (30) days following the first
achievement of the following research milestones: 
  

					
	 Research Milestones
	  	Payment Amount	 
	1. Identification of the second Development Candidate directed against the Raf Target (it being acknowledged and agreed that [ * ] is the first such Licensed Compound for the
Raf Target):	  	 	$[ * ]	  
		
	2. Identification of the second Development Candidate directed against the [ * ] Target (it being acknowledged and agreed	  			

  
 -23-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

			
	 Research Milestones
	  	Payment Amount
	that, as of the Effective Date, no GLP toxicity study or GMP manufacturing has been initiated for the first such Licensed Compound):	  	$[ * ]

 6.2.
Development Milestones. 
 6.2.1 Development Milestone Payments. 

(a) Millennium shall pay Sunesis [ * ] Dollars ($[ * ]) within thirty (30) days following the initiation of the first
Phase I trial for a Licensed Product directed against the [ * ] Target. 
 (b) With respect to each Licensed Product,
Millennium shall pay to Sunesis on a Licensed Product-by-Licensed Product basis the following amounts within thirty (30) days following the first achievement by Millennium, its Affiliates or Sublicensees, as the case may be, of each of the
following milestones with respect to such Licensed Product: 
  

			
	 	  	Payment Amount
	 Development Milestones
	  	[ * ]

 [
* ] 
 Such milestone payments shall be non-refundable and non-creditable against other amounts due Sunesis hereunder.

 6.2.2 Certain Additional Terms. 
 (a) Licensed Product-by-Licensed Product Milestones. It is understood that, subject to Section 6.2.2(b), the payments under this Section 6.2 shall be due only once with respect to each
Licensed Product. 
 (b) Multiple Indications. With respect to a particular Licensed Product, [ * ] 

(c) Discontinued Licensed Products. If Millennium ceases all clinical development of a particular Licensed Product, after having
made one or more of the payments due under Section 6.2.1 above on the achievement of a particular milestone by such Licensed Product, there shall be no payment due upon the accomplishment of that same milestone with respect to the next Licensed
Product that is specifically directed at the same Designated Target to achieve such milestone. 

  
 -24-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 (d) Accrued Milestones. If a development milestone for a Licensed Product under
Section 6.2.1 above is achieved with respect to such Licensed Product before a prior development milestone under Section 6.2.1 for such Licensed Product, then the earlier milestone payments shall then also be due with respect to such
Licensed Product. 
 6.2.3 Reports; Payments. Within ten (10) business days of the occurrence of any event which
would trigger a milestone payment according to Section 6.2, Millennium shall inform Sunesis of such occurrence. The corresponding payment shall be due thirty (30) days after the occurrence of such event. 

6.3. Royalties on Annual Net Sales of Licensed Products. 
 6.3.1 Licensed Products Generally. Subject to Sections 6.3.2 and 6.3.3, Millennium shall pay to Sunesis a royalty on Net Sales by Millennium, its Affiliates and their Sublicensees of Licensed
Products (other than Net Sales of Co-Funded Products in the Co-Funded Territory) on a Licensed Product-by-Licensed Product basis, equal to the percentage of such Net Sales set forth below: 

 

			
	Annual Net Sales	  	Royalty on Net Sales
		
	 Portion of Annual Net Sales of such Licensed Product up to $[ * ]:
	  	[ * ]%
		
	 Portion of Annual Net Sales of such Licensed Product between $[ * ] and $[ * ]:
	  	[ * ]%
		
	 Portion of Annual Net Sales of such Licensed Product between $[ * ] and $[ * ]:
	  	[ * ]%
		
	 Portion of Annual Net Sales of such Licensed Product over $[ * ]:
	  	[ * ]%

 For purposes of
the foregoing and Section 6.3.2 below, “Annual Net Sales” shall mean, for a particular Licensed Product, the worldwide Net Sales of such Licensed Product for the particular calendar year. In the event that in a calendar quarter
portions of the worldwide Net Sales of a particular Licensed Product are subject to royalty obligations under both Sections 6.3.1 and 6.3.2, the applicable royalty rate under Section 6.3.2 shall be applied to worldwide Net Sales based on the
proportion of worldwide Net Sales generated in the Co-Funded Territory. 
 6.3.2 Compensation for Co-Funded Products.

 (a) Subject to Sections 6.3.2(b), 6.3.2(c) and 6.3.3, in consideration for the co-funding by Sunesis, Millennium shall pay to
Sunesis an amount [ * ]  
 (b) [ * ] 
 [ * ] 
 6.3.3 Third Party Patents. 

  
 -25-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 (a) If: (i) a [ * ] of a Third Party should be in force in any country
during the Term of this Agreement covering the practice of the Sunesis Licensed Technology or Sunesis Core Technology as licensed to Millennium under Section 5.1 with respect to the manufacture, use or sale of any Licensed Product, (ii) it
should prove in Millennium’s reasonable judgment, after consultation with Sunesis, [ * ] for Millennium to commercialize such Licensed Product without obtaining a royalty bearing license from such Third Party [ * ] (with such
agreement not to be unreasonably withheld or delayed), and (iii) the royalty paid to such Third Party is directed to the practice of rights granted to Millennium under Section 5.1 with respect to such Licensed Product, then Millennium
shall be entitled to a credit against the royalty payments due under the other provisions of this Section 6.3 with respect to the same Licensed Product in such country of an amount equal to [ * ] of the royalty paid to such Third Party
for such Licensed Product in such country, arising from the practice of such Sunesis Licensed Technology or Sunesis Core Technology with respect to the manufacture, use or sale of the Licensed Product in said country, with such credit not to exceed
[ * ] of the royalty otherwise due under this Agreement for such Licensed Product in such country. 
 (b) If: (i) a
[ * ] of a Third Party should be in force in any country during the Term of this Agreement covering the practice of the Biogen Idec Collaboration Technology, Joint Sunesis-Biogen Collaboration Technology, Development Technology or Other
Millennium Technology licensed to Sunesis under Section 5.1.3, in each case with respect to the manufacture, use or sale of any Reverted Licensed Product, (ii) it should prove in Sunesis’s reasonable judgment, after consultation with
Millennium, [ * ] for Sunesis to commercialize such Reverted Licensed Product without obtaining a royalty bearing license from such Third Party [ * ] (with such agreement not to be unreasonably withheld or delayed), and (iii) the
royalty paid to such Third Party is directed to the practice of rights granted to Sunesis under Section 5.1.3 with respect to such Reverted Licensed Product, then Sunesis shall be entitled to a credit against the royalty payments due under
Section 6.4 with respect to the same Reverted Licensed Product in such country of an amount equal to [ * ] of the royalty paid to such Third Party for such Reverted Licensed Product in such country, arising from the practice of the
intellectual property described above with respect to the manufacture, use or sale of the Reverted Licensed Product in said country, with such credit not to exceed [ * ] of the royalty otherwise due under this Agreement for such Reverted
Licensed Product in such country. 
 6.4. Royalties on Net Sales of Reverted Licensed Products. Sunesis shall pay
Millennium at a royalty rate equal to the royalty rate provided under Section 6.3.1 with respect to Net Sales of Reverted Licensed Products by Sunesis, its Affiliates and their Sublicensees; provided, however, that such royalty rate shall be
[ * ] by [ * ] with respect to sales in the U.S. or Japan during any portion of the applicable period under clause (ii) in Section 6.5.1 in which [ * ] the Biogen Idec Collaboration Patents, Joint Sunesis-Biogen
Collaboration Patents, Development Technology or Other Millennium Technology Covers the sale or use of such Reverted Licensed Product in such country. 
 6.5. Royalty Term. 

  
 -26-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 6.5.1 The royalties due pursuant to Section 6.3 and Section 6.4 above shall be
payable on a country-by-country and Product-by-Product basis commencing on the first commercial sale in a country and continuing until the later of: [ * ]  
 6.5.2 Millennium acknowledges that it will continue to benefit from its license under, and the transfer to Millennium of certain elements of, the Sunesis Collaboration Technology and Sunesis Core
Technology, the co-funding payments pursuant to this Agreement and Millennium’s own development of Know-How derived from the practice of such Sunesis licenses and Millennium’s use of such Sunesis Collaboration Technology and Sunesis Core
Technology, even after the expiration of all Patent Rights that claim a Licensed Product in a particular country of the Territory. In addition, Millennium and Sunesis acknowledge the application of a uniform royalty structure and compensation to
Sunesis for its co-funding payments in the form of an additional royalty payment amount throughout the period under clause (ii) in Section 6.5.1. The Parties acknowledge that such structure is more convenient to the Parties, facilitates
the payment of compensation between the Parties for co-funding commitments and access to Know-How and reduces accounting burdens on the Parties. Accordingly, the Parties have agreed to apply the royalty structure as provided in this Article 6.

 ARTICLE 7 
 PAYMENTS, BOOKS AND RECORDS 
 7.1. Royalty Reports and Payments.
After the first sale of a Product on which royalties are payable by a Party hereunder, such Party shall make quarterly written reports to the other Party within sixty (60) days after the end of each calendar quarter, stating in each such
report, separately the number, description, and aggregate Net Sales, by territory, of each such Product sold during the calendar quarter upon which a royalty is payable under Section 6.3 or Section 6.4 above, as applicable. Concurrently
with the making of such reports, such Party shall pay to the other Party royalties due at the rates specified in Section 6.3 or Section 6.4 above, as applicable. 
 7.2. Payment Method. All payments due under this Agreement shall be made by bank wire transfer in immediately available funds to a bank account designated by the Party owed such payment. All
payments hereunder shall be made in U.S. dollars. Any payments that are not paid on the date such payments are due under this Agreement shall bear interest to the extent permitted by applicable law at a rate equal to the 3-month LIBOR rate at the
close of business on the date such payment is due, plus an additional two percent (2%), calculated on the number of days such payment is delinquent. 
 7.3. Place of Royalty Payment; Currency Conversion. The functional currency for accounting will be U.S. dollars. Except as the Parties otherwise mutually agree, for billing and reporting,
Development Costs and Net Sales will be translated, if necessary, into U.S. dollars using the currency exchange rates quoted by Bloomberg Professional, a service of Bloomberg L.P., or in the event Bloomberg Professional is not
available, then the Eastern U.S. edition of The Wall Street Journal on the last business day of the applicable calendar quarter. 

  
 -27-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 7.4. Records; Inspection. Each Party shall keep, and shall ensure that its
Affiliates keep, complete, true and accurate books of account and records for the purpose of determining the amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of such Party, for at least
three (3) years following the end of the calendar quarter to which they pertain. Such records will be open for inspection by a public accounting firm to whom the audited Party has no reasonable objection and subject to such accounting firm
entering into a satisfactory confidentiality agreement, solely for the purpose of determining the payments to the other Party hereunder. Such inspections may be made no more than twice each calendar year, at reasonable times and on reasonable
notice. Inspections conducted under this Section 7.4 shall be at the expense of the auditing Party, unless a variation or error producing an increase exceeding [ * ] percent ([ * ]%) of the amount stated for the period covered by
the inspection is established in the course of any such inspection, whereupon all reasonable costs relating to the inspection for such period and any unpaid or overpaid amounts that are discovered will be promptly paid or refunded by the appropriate
Party, in each case together with interest noted in Section 7.2 thereon from the date such payments were due (if underpaid) or paid (if overpaid). 
 7.5. Withholding Taxes. Each Party shall pay any and all taxes levied on account of amounts payable to it under this Agreement. If laws or regulations require that taxes be withheld, the paying
Party will (i) deduct those taxes from the remittable payment, (ii) timely pay the taxes to the proper authority, and (iii) send proof of payment to the other Party within sixty (60) days following that payment. 

ARTICLE 8 

DILIGENCE 

8.1. Diligence; Reports. Millennium shall use Commercially Reasonable and Diligent Efforts to develop and commercialize Co-Funded
Products within the Field. Millennium agrees to keep Sunesis fully informed regarding the Development and commercialization activities with respect to each Co-Funded Product by providing reports to Sunesis at least quarterly regarding ongoing
activities being undertaken with respect to Co-Funded Products. In addition, Millennium shall provide Diligence Summaries to Sunesis with respect to each [ * ]. This Section 8.1 shall not limit other provisions of this Agreement that
address the provision of information regarding Licensed Products. 
 8.2. Reversion of a Co-Funded Product. If Millennium
fails to use Commercially Reasonable and Diligent Efforts to develop and commercialize a Co-Funded Product, and Millennium shall continue to fail to use Commercially Reasonable and Diligent Efforts to develop and commercialize such Co-Funded Product
for [ * ] after written notice thereof from Sunesis, or in the event that Sunesis terminates this Agreement pursuant to Section 13.2 for Millennium’s breach, pursuant to Section 13.3 for Millennium’s bankruptcy or in the
event that Millennium terminates this Agreement pursuant to Section 13.4 for convenience with respect to a Co-Funded Product, Sunesis shall have the right to assume the development and commercialization of such Co-Funded Product, subject to the
terms and conditions of this Section 8.2, upon written notice to Millennium. Upon the effective date of such notice from 

  
 -28-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
Sunesis, such Co-Funded Product shall be designated a “Reverted Licensed Product”, the terms set forth in Section 1 of Exhibit 8.2 attached hereto shall thereafter apply, and
Sunesis shall pay royalties to Millennium as provided under Section 6.4 on Net Sales of such Reverted Licensed Product by Sunesis, its Affiliates or Sublicensees. 
 8.3. Diligence for a Reverted Licensed Product. Sunesis shall use Commercially Reasonable and Diligent Efforts to develop and commercialize each Reverted Licensed Product. Sunesis agrees to keep
Millennium fully informed regarding the development and commercialization activities with respect to each Reverted Licensed Product, including by providing Millennium with reports at least quarterly regarding ongoing activities being undertaken with
respect to Reverted Licensed Products. In addition, Sunesis shall provide Millennium with a Diligence Summary with respect to each Reverted Licensed Product on a semi-annual basis during the Term of this Agreement. 

8.4. Termination of a Reverted Licensed Product. If Sunesis fails to use Commercially Reasonable and Diligent Efforts to develop
and commercialize a Reverted Licensed Product, and Sunesis shall continue to fail to use Commercially Reasonable and Diligent Efforts to develop and commercialize such Reverted Licensed Product for sixty (60) days after written notice thereof
from Millennium, then such Reverted Licensed Product shall cease to be a Reverted Licensed Product, and the license granted to Sunesis under Section 5.1.3 shall terminate with respect to such Reverted Licensed Product. Thereafter, such Reverted
Licensed Product shall be a Licensed Product and subject to Millennium’s licenses under Section 5.1 and obligations to pay royalties and milestones to Sunesis pursuant to Article 6. In addition, the terms set forth in Section 2 of
Exhibit 8.2 shall apply to such Reverted Licensed Product. 
 8.5. Disputes. In the event that there is a good faith
dispute as to whether the activities described in a Diligence Summary constitute Commercially Reasonable and Diligent Efforts to develop and commercialize the applicable Co-Funded Product or Reverted Licensed Product, then either Party may refer the
dispute for a prompt determination by the JSC. In the event that the JSC is unable to reach consensus on such determination, then the matter shall be referred to the Parties’ respective Chief Medical Officers (or the equivalent if there is no
such Chief Medical Officer of a Party). Upon such request, the Chief Medical Officers shall make themselves reasonably available to meet, and shall meet either by telephone or if, specifically requested, in person, to attempt to resolve such matter,
and shall thereafter continue to use good faith efforts to attempt to resolve such matter unless it becomes clear that the matter cannot be resolved by mutual agreement. Thereafter either Party may pursue such legal process as is otherwise available
under applicable law. 

  
 -29-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 ARTICLE 9 
 INTELLECTUAL PROPERTY 
 9.1. Ownership; Disclosure. 

9.1.1 Collaboration Technology. 
 (a) Raf Technology. All right, title, and interest in and to the Sunesis Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents, the subject of which are inventions that were
developed in the course of activities directed to the Raf Target or to the discovery, research, or development of Licensed Compounds which are Target Selective to the Raf Target or Licensed Products incorporating such Licensed Compounds (the
“Raf Patents”) were jointly and equally owned by Biogen Idec and Sunesis under the Original Agreement. Pursuant to the Millennium-Biogen Agreement, Biogen Idec has, with the consent of Sunesis as provided in the Three Party Agreement,
assigned all of its right, title and interest in and to the Raf Patents to Millennium; and from and after the Effective Date the Raf Patents shall be jointly owned by Millennium and Sunesis. 

(b) Sunesis Collaboration Technology. Subject to Section 9.1.1(a), all right, title, and interest in and to the Sunesis
Collaboration Technology shall be owned by Sunesis, subject to the licenses granted to Millennium under Article 5. 
 (c)
Joint Sunesis-Biogen Collaboration Technology. Pursuant to the Millennium-Biogen Agreement, Biogen Idec has, with the consent of Sunesis as provided in the Three Party Agreement, assigned to Millennium all of its right, title and interest in
and to the Joint Sunesis-Biogen Collaboration Patents and Joint Sunesis-Biogen Collaboration Know-How that are included in the Assigned IP (as defined in the Millennium-Biogen Agreement) and that, in each case, are [ * ] a Licensed Compound
(the “Licensed Compound Joint Technology”) and has granted a license to Millennium under Biogen Idec’s right, title and interest in and to all other Joint Sunesis-Biogen Patents and Joint Sunesis-Biogen Know-How (the “Other Joint
Technology”). All right, title and interest in and to the Licensed Compound Joint Technology shall be jointly owned by the Parties. All right, title and interest in and to the Other Joint Technology shall be jointly owned by Sunesis and Biogen
Idec (subject to the licenses granted to Millennium). Except as expressly provided in this Agreement, neither Party shall have any obligation to account to the other for profits, or to obtain any approval of the other Party to license, exploit or
enforce the Licensed Compound Joint Technology, by reason of joint ownership thereof, and each Party hereby waives any right it may have under the laws of any jurisdiction to require any accounting or consent related thereto. It is understood and
agreed that all Joint Sunesis-Biogen Collaboration Technology that is jointly owned pursuant to Section 9.1.1(a) and this Section 9.1.1(c) shall be subject to the licenses granted under Article 5. 

(d) Excluded Compounds. For the avoidance of doubt, to the extent a Joint Sunesis-Biogen Collaboration Patent discloses any use
of an Excluded Compound (as defined in the Original Agreement), the composition of matter of which is separately owned by one Party, the other Party shall not have, merely as a result of its joint ownership of such Joint

  
 -30-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
Sunesis-Biogen Collaboration Patent, any right, title or interest in or to such Excluded Compound. 
 9.1.2 Development Technology. All right, title and interest in and to the Development Technology shall, as between the Parties, be owned solely by Millennium. Sunesis hereby assigns to Millennium
all of Sunesis’s and its Affiliates’ rights in and to the Development Technology (including all patent and other intellectual property rights therein), subject to the licenses granted to Sunesis under Article 5. 

9.2. Patent Prosecution. Subject to the rights of Biogen Idec under the Millennium-Biogen Agreement: 

9.2.1 Sunesis Core Technology. Sunesis shall have the right to control the preparation, filing, prosecution and maintenance of
patent applications and patents directed to Sunesis Core Technology using patent counsel of Sunesis’s choice, provided that such decisions made by Sunesis in the preparation, filing, prosecution, and maintenance of such patents and patent
applications shall be reasonable and Sunesis shall employ reasonable efforts not to substantially negatively impact Millennium’s rights hereunder. 
 9.2.2 Collaboration Patents. Millennium shall have the first right, using in-house or outside legal counsel selected by Millennium, subject to approval, not to be unreasonably withheld, by Sunesis,
to prepare, file, prosecute, maintain, and obtain extensions of Collaboration Patents throughout the world. Millennium shall: (a) ensure that Sunesis receives copies of all correspondence between Millennium or outside legal counsel or any
governmental offices relating to such preparation, filing, prosecution, maintenance, and obtaining of extensions, of such Collaboration Patents, (b) timely consult with Sunesis regarding all substantive matters associated with such activities,
(c) use reasonable efforts to periodically advise Sunesis on such activities and to respond to any reasonable inquiries Sunesis may from time to time raise in respect of such activities, and (d) not substantially negatively impact
Sunesis’s rights under such Collaboration Patents. As used herein, “prosecution” shall include interferences, re-examinations, reissues, oppositions and the like. 

9.2.3 Prosecution Costs. During the Term of this Agreement, all costs associated with filing, prosecuting, issuing, maintaining,
and extending (i) patent applications and patents within the Sunesis Core Technology shall be borne by Sunesis; and (ii) the Collaboration Patents shall be borne by Millennium. 

9.2.4 Cooperation. Each Party will cooperate fully with the other Party and provide all information and data, and sign any
documents, reasonably necessary and requested by the other Party for the purpose of preparing, filing and prosecuting patent applications pursuant to this Section 9.2. 
 9.2.5 Abandonment. Millennium may elect to decline to file or, having filed, decline to further prosecute and maintain any Collaboration Patent, in which event Millennium shall provide Sunesis with
written notice thereof prior to the expiration of any deadline, without considering any possible extensions thereof, relating to such activities, but in any event at least 

  
 -31-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
thirty five (35) business days prior notice. In such circumstances Sunesis shall have the right to decide, with reason and with written notice at least thirty (30) business days prior
to the deadline, that Millennium should continue to file or prosecute such Collaboration Patent. Millennium shall then have the option to decide, with at least twenty (20) business days notice to Sunesis to: (i) continue to file or
prosecute such Collaboration Patent at its cost and expense, or (ii) allow Sunesis to file or prosecute such Collaboration Patent at its own cost and expense using counsel of its own choice. In the event that Millennium elects option (ii), then
Millennium shall cooperate with Sunesis to promptly transfer relevant prosecution materials to Sunesis. It is understood and agreed that transfer of prosecution of particular Collaboration Patents pursuant to subsection (ii) above shall not
affect the ownership or licenses otherwise provided in this Agreement. 
 9.3. Enforcement. Subject to the rights of
Biogen Idec under the Millennium-Biogen Agreement: 
 9.3.1 Notice. In the event a Party becomes aware of any actual or
potential infringement or misappropriation of the Sunesis Licensed Technology (a “Subject Infringement”), such Party shall notify the other Party. 
 9.3.2 Millennium. Subject to the terms of this Section 9.3.2, Millennium shall have the sole right, but not the obligation, to take legal action to enforce and defend the Sunesis Licensed
Technology against Subject Infringements by Third Parties at its sole cost and expense, to the extent such Subject Infringement is within the field of use of Millennium’s exclusive license under Section 5.1.1 above. If, within [ * ]
following a request by Sunesis to do so, Millennium fails to take such action to enforce the Sunesis Licensed Patents with respect to a Subject Infringement, Sunesis or its designee shall, in its sole discretion, have the right, at its sole expense,
to take such action. In addition, Millennium shall have the sole right, but not the obligation, to take legal action to enforce and defend any actual or potential infringement or misappropriation of the Biogen Idec Collaboration Technology.

 9.3.3 Sunesis. To the extent a Subject Infringement is not covered by Section 9.3.2 above, Sunesis (or its
designee) shall have the initial right, but not the obligation, to take reasonable legal action to enforce and defend the Sunesis Licensed Technology against such Subject Infringements by Third Parties at its sole cost and expense. If, within [ *
] following a request by Millennium to do so, Sunesis fails to take such action to enforce the Sunesis Licensed Patents with respect to such Subject Infringement, and the Subject Infringement is in a field not then licensed exclusively to
Sunesis hereunder, Millennium or its designee shall, in its sole discretion, have the right, at its sole expense, to take such action. 
 9.3.4 Cooperation; Costs and Recoveries. If a Party (the “Controlling Party”) brings an action with respect to a Subject Infringement in accordance with this Section 9.3 (an
“Infringement Action”), then the other Party (the “Cooperating Party”) shall cooperate as reasonably requested, at such Controlling Party’s expense, in the pursuit of such Infringement Action, including if necessary by
joining as a nominal Party to the Infringement Action. In any case, the Cooperating Party shall have the right, even if not required to be joined, to participate in 

  
 -32-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
such Infringement Action with its own counsel at its own expense. The costs and expenses of the Infringement Action shall be the responsibility of the Controlling Party, and any damages or other
monetary rewards or settlement payments actually received and retained by the Controlling Party shall first be applied to reimburse the Controlling Party’s out-of-pocket expenses directly attributed to the Infringement Action, then the other
Party’s out-of-pocket expenses directly attributed to the Infringement Action, and the remainder shall be shared as follows: [ * ] 
 ARTICLE 10 
 CONFIDENTIALITY 

10.1. Confidentiality. During the Term of this Agreement and for a period of [ * ] years following the expiration or
earlier termination hereof, each Party shall maintain in confidence the Confidential Information of the other Party, shall not use or grant the use of the Confidential Information of the other Party except as expressly permitted hereby, and shall
not disclose the Confidential Information of the other Party (in each case, irrespective of whether such Confidential Information is also the Confidential Information of the receiving Party), except (i) on a need-to-know basis to such
Party’s directors, officers and employees, (ii) to such Party’s consultants performing work contemplated by the Agreement, and to any bona fide subcontractor performing work for such Party hereunder, or (iii) to the extent such
disclosure is reasonably necessary in connection with such Party’s activities under rights and licenses expressly authorized by this Agreement (including the permitted sublicensees). To the extent that disclosure to any person is authorized by
this Agreement, prior to disclosure, a Party shall obtain written agreement of such person to hold in confidence and not disclose, use or grant the use of the Confidential Information of the other Party except as expressly permitted under this
Agreement. Each Party shall notify the other Party promptly upon discovery of any unauthorized use or disclosure of the other Party’s Confidential Information. 
 10.2. Permitted Use and Disclosures. The confidentiality obligations under this Article 10 shall not apply to the extent that a Party is required to disclose information by applicable law,
regulation or order of a governmental agency or a court of competent jurisdiction; provided, however, that such Party shall provide written notice thereof to the other Party (to the extent not prohibited by law or court order), and
consult with the other Party with respect to such disclosure to the extent reasonably protectable and provide the other party reasonable opportunity to object to any such disclosure or to request confidential treatment thereof. Notwithstanding the
provisions of this Section, either Party may, to the extent necessary, disclose Confidential Information of the other Party, to any governmental or regulatory authority in connection with the development of a product which it has the right to
develop under this Agreement. 
 10.3. Nondisclosure of Terms. Each of the Parties hereto agrees not to disclose the
financial terms of this Agreement to any Third Party without the prior written consent of the other Party hereto, which consent shall not be unreasonably withheld, except (a) to such Party’s attorneys, advisors, investors, potential
bona fide collaborators and Sublicensees, and others on a need-to-know basis under circumstances that reasonably protect the confidentiality thereof; (b) or to the extent required by law (and with appropriate requests made for
confidential treatment), 

  
 -33-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
including filings required to made by law with the Securities and Exchange Commission or any national securities exchange; provided, however, that, with respect to any filing required to made by
law with the Securities and Exchange Commission or any national securities exchange, the Party subject to such filing requirement shall, at least ten (10) business days in advance of any such filing, provide the other Party with a draft set of
redactions to this Agreement for which confidential treatment will be sought, reasonably incorporate the other Party’s comments as to additional terms it would like to see redacted, and seek confidential treatment for such additional terms
(except only in the limited circumstances where confidential treatment is in the opinion of outside counsel unavailable); or (c) to Biogen Idec, to the extent required under the Three Party Agreement or Millennium-Biogen Agreement.
Notwithstanding the foregoing, (i) Sunesis may issue the press release to be mutually agreed by the Parties, and (ii) each Party may disclose the information contained in such press release (and related Securities and Exchange Commission
filing) without the consent of the other Party. 
 10.4. Publication. 

10.4.1 By Sunesis. Any manuscript by Sunesis on subject matter in connection with the Research Program relating to the Designated
Targets or Licensed Compounds to be published or publicly disclosed shall be subject to the prior review of Millennium at least [ * ] prior to submission. Further, to avoid loss of patent rights as a result of premature public disclosure of
patentable information, Millennium shall notify Sunesis in writing within [ * ] after receipt of any disclosure whether Millennium desires to file a patent application on any invention disclosed in such scientific results. In the event that
Millennium desires to file such a patent application, Sunesis shall withhold publication or disclosure of such scientific results until the earlier of (i) a patent application is filed thereon, (ii) the Parties determine after consultation
that no patentable invention exists, or (iii) [ * ] after receipt by Sunesis of Millennium’s written notice of Millennium’s desire to file such patent application. Further, if such scientific results contain the information of
Millennium that is subject to use and nondisclosure restrictions under this Article 10, Sunesis agrees to remove such information from the proposed publication or disclosure. For clarity, nothing in this Section 10.4 shall be deemed to
limit the publication or disclosure right of Sunesis with respect to a Reverted Licensed Product. 
 10.4.2 By
Millennium. Millennium shall have the right, but not the obligation, to publish or publicly disclose, in its sole discretion, any manuscript containing scientific or clinical results generated during the Term relating to the Designated Targets,
Licensed Compounds or Licensed Products, and shall provide Sunesis with a courtesy copy of such manuscript prior to its publication. 
 10.4.3 Patent Applications. Following the filing of any patent application within the Collaboration Technology, in the period prior to the publication of such a patent application, neither Party
shall make any written public disclosure regarding any invention claimed in such patent application without the prior consent of the other Party. 

  
 -34-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 ARTICLE 11 
 REPRESENTATIONS AND WARRANTIES 
 11.1. Warranty. Each Party
represents and warrants on its own behalf and on behalf of its Affiliates that: 
 (i) Such Party is duly organized, validly
existing and in good standing under the laws of the jurisdiction in which it is organized. 
 (ii) It has the legal power and
authority to enter into this Agreement and to perform all of its obligations hereunder. 
 (iii) This Agreement is a legal and
valid obligation binding upon it and enforceable in accordance with its terms. 
 (iv) All necessary consents, approvals and
authorizations of all governmental authorities and other persons or entities required to be obtained by such Party in connection with this Agreement have been obtained. 
 (v) The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable laws, regulations or
orders of governmental bodies; and (b) do not conflict with, or constitute a default under, any contractual obligation of such Party. Neither Party will enter into any agreement with any Third Party that conflicts with the terms of this
Agreement. 
 (vi) Such Party requires, and shall require, that all of its employees and consultants involved in the
Development, manufacture or commercialization of Licensed Compounds, Licensed Products, Reverted Compounds or Reverted Licensed Products have entered into written agreements obligating such person to assign any rights s/he may have in any inventions
made during such work to such Party. 
 11.2. Additional Warranty of Sunesis. Sunesis represents and warrants as of the
Effective Date that: 
 (a) to the best of its knowledge, the practice of the Sunesis Core Technology with respect to the
Licensed Compounds is not generally dominated by Patent Rights of a Third Party; 
 (b) Sunesis has not received any notice of
infringement from any Third Party relating to the Sunesis Core Technology or Sunesis Licensed Technology; 
 (c) Sunesis has
not received any notice challenging the validity of the Sunesis Licensed Technology or Sunesis Core Technology; and 

  
 -35-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 (d) to the best of its knowledge, the Sunesis Licensed Technology and Sunesis Core
Technology with respect to Licensed Compounds is legally possessed by Sunesis and has not been misappropriated from any Third Party. 
 11.3. Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE
COLLABORATION TECHNOLOGY, SUNESIS CORE TECHNOLOGY, DEVELOPMENT TECHNOLOGY, OTHER MILLENNIUM TECHNOLOGY, LICENSED COMPOUNDS, OTHER COMPOUNDS, LICENSED PRODUCTS, DESIGNATED TARGETS OR CONFIDENTIAL INFORMATION, INCLUDING WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF ANY COLLABORATION TECHNOLOGY, PATENTED OR UNPATENTED, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 ARTICLE 12 
 INDEMNIFICATION 

12.1. Millennium. Millennium shall indemnify, defend and hold harmless Sunesis and its Affiliates and their respective directors,
officers, employees, agents and their respective successors, heirs and assigns from and against any losses, costs, claims, damages, liabilities or expense (including reasonable attorneys’ and professional fees and other expenses of litigation)
(collectively, “Liabilities”) resulting from any claims, demands, actions or other proceedings by any Third Party to the extent resulting from: (i) the manufacture, use, sale, handling or storage of Licensed Products by Millennium or
its Affiliates or Sublicensees or other designees (except with respect to claims of infringement or violation of intellectual property rights, which shall be governed solely by clause (iv)); (ii) the breach by Millennium of the
representations and warranties made in this Agreement; (iii) [ * ] Millennium or any of its agents or employees or failure of Millennium or any of its agents or employees to comply with applicable laws and regulations; or (iv) a
claim that the use, manufacture, sale or importation of a Licensed Product infringes or violates the intellectual property rights of a Third Party (other than if such infringement or violation results solely from the practice of any Sunesis Licensed
Technology (excluding any Joint Sunesis-Biogen Idec Collaboration Patents and Joint Sunesis-Biogen Idec Collaboration Know-How) and Sunesis Core Technology in accordance with this Agreement); except, in each of cases (i)–(iv), to the extent
such Liabilities result from a material breach of this Agreement by Sunesis, [ * ] Sunesis or any of its agents or employees (including sales representatives involved in co-promoting any Co-Promoted Licensed Product) or failure of Sunesis or
any of its employees or agents to comply with applicable laws or regulations. 
 12.2. Sunesis. Sunesis agrees to
indemnify, defend and hold harmless Millennium and its Affiliates and their respective directors, officers, employees, agents and their respective heirs and assigns from and against any Liabilities resulting from any claims, demands, actions or
other proceedings by any Third Party to the extent resulting from: (i) the manufacture, use, sale, handling or storage of Co-Promoted Licensed Products or Reverted Licensed Products by 

  
 -36-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
Sunesis or its Affiliates or Sublicensees or other designees, (ii) the breach by Sunesis of its representations and warranties made in this Agreement or the Original Agreement, or
(iii) [ * ] Sunesis or any of its agents or employees or failure of Sunesis or any of its agents or employees to comply with applicable laws and regulations; except, in each case, to the extent such Liabilities result from a breach of
this Agreement by Millennium, [ * ] Millennium or any of its agents or employees (including sales representatives involved in co-promoting any Co-Promoted Licensed Product) or failure of Millennium or any of its employees or agents to comply
with applicable laws or regulations. 
 12.3. Procedure. If a Party (the “Indemnitee”) intends to claim
indemnification under this Article 12, it shall promptly notify the other Party (the “Indemnitor”) in writing of any claim, demand, action or other proceeding for which the Indemnitee intends to claim such indemnification, and the
Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, to assume the defense thereof with counsel mutually satisfactory to the Parties; provided, however, that an Indemnitee shall have the right to retain
its own counsel, with the fees and expenses to be paid by the Indemnitor, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between the Indemnitee and
any other Party represented by such counsel in such proceeding. The obligations of this Article 12 shall not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of
the Indemnitor, which consent shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, if prejudicial to its ability to defend such
action, shall relieve the Indemnitor of any obligation to the Indemnitee under this Article 12. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any claim,
demand, action or other proceeding covered by this Article 12. The Indemnitor shall not, without the Indemnitee’s consent, which consent shall not be withheld or delayed unreasonably, consent to the entry of any judgment or accept any
settlement with respect to such claim, demand, action or proceeding which imposes liability not covered by this indemnification or restrictions on the Indemnitee. 
 ARTICLE 13 
 TERM AND TERMINATION 

13.1. Term. The Term of this Agreement shall commence on the Effective Date, and shall continue in full force and effect on a
country-by-country and Product-by-Product basis until expiration of both Parties’ royalty payment obligations in such country with respect to such Products, in each case unless earlier terminated as provided in this Article 13 (the
“Term”). 
 13.2. Termination for Breach. Either Party to this Agreement may terminate this Agreement in the
event the other Party hereto shall have materially breached or defaulted in the performance of any of its material obligations hereunder, and such default shall have continued for [ * ] after written notice thereof was provided to the
breaching Party by the non-breaching Party. Any termination shall become effective at the end of such [ * ] period unless the breaching Party has cured any such breach or default prior to the expiration of the [ * ] period.

  
 -37-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
Notwithstanding the foregoing, failure by either Party to use Commercially Reasonable and Diligent Efforts with respect to the development and commercialization of a Product shall not be deemed a
breach of this Agreement. Sunesis hereby waives any breaches or defaults by Biogen Idec under the Original Agreement and acknowledges and agrees that any future breaches or defaults by Biogen Idec under the New Sunesis-Biogen Agreement shall have no
bearing on this Agreement. 
 13.3. Termination For Bankruptcy. Either Party hereto shall have the right to terminate
this Agreement forthwith by written notice to the other Party (i) if the other Party is declared insolvent or bankrupt by a court of competent jurisdiction, (ii) if a voluntary or involuntary petition in bankruptcy is filed in any court of
competent jurisdiction against the other Party and such petition is not dismissed within ninety (90) days after filing, (iii) if the other Party shall make or execute an assignment of substantially all of its assets for the benefit of
creditors, or (iv) substantially all of the assets of such other Party are seized or attached and not released within ninety (90) days thereafter. All rights and licenses granted under this Agreement by one Party to the other Party are,
and shall otherwise be deemed for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 (56) of the Bankruptcy Code. The Parties agree that the
licensing Party under this Agreement shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code in the event of a bankruptcy by the other Party. The Parties further agree that in the event of the commencement of a
bankruptcy proceeding by or against one Party under the Bankruptcy Code, the other Party shall be entitled to complete access to any such intellectual property pertaining to the rights granted in the licenses hereunder of the Party by or against
whom a bankruptcy proceeding has been commenced and all embodiments of such intellectual property. 
 13.4. Termination for
Convenience by Millennium. Provided that Millennium is not in breach of this Agreement, Millennium will have the right to terminate this Agreement at any time, by providing [ * ] prior written notice. 

13.5. Effect of Breach or Termination. 
 13.5.1 Accrued Rights and Obligations. Termination of this Agreement for any reason shall not release either Party hereto from any liability which, at the time of such termination, has already
accrued to the other Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement.

 13.5.2 Termination by Millennium for Breach or Bankruptcy of Sunesis. In the event of termination of this Agreement by
Millennium pursuant to Section 13.2 due to Sunesis’s breach or by Millennium pursuant to Section 13.3 for Sunesis’s bankruptcy, in addition to those provisions surviving under Section 13.8, the following shall apply:

 (a) Sections 2.5.1 (Research Records); 2.5.2 (Inspections) (but only with respect to Millennium’s rights and
Sunesis’s obligations); 5.1.3 (License for Reverted Licensed Products) (but only with respect to Reverted Licensed Products in existence as of the effective date of such termination); 6.1 (Research Milestones); 6.2 (Development Milestones); 6.3

  
 -38-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
(Royalties on Annual Net Sales of Licensed Products) (except that any royalties payable by Millennium thereunder, commencing upon such termination and continuing thereafter, shall be reduced by
[ * ]); 6.4 (Royalties on Net Sales of Reverted Licensed Products); 6.5 (Royalty Term); Article 9 (Intellectual Property) (other than Sections 9.2.2 and 9.2.3, which shall terminate); and Exhibit 8.2 (Reverted Licensed Products) (but only
with respect to Reverted Licensed Products in existence as of the effective date of such termination) shall survive. 
 (b)
Subject to the rights of Biogen Idec under the Millennium-Biogen Agreement, Millennium shall control prosecution of all Collaboration Patents (including Sunesis Collaboration Patents, Biogen Idec Collaboration Patents and Joint Sunesis-Biogen
Collaboration Patents) at its own expense. Sunesis shall be given the opportunity to review Millennium’s activities and reasonably consult with Millennium with respect to Sunesis Collaboration Patents and Joint Sunesis-Biogen Collaboration
Patents, and Millennium shall in good faith consider including in such patent applications such claims as Sunesis reasonably requests. Millennium shall keep Sunesis reasonably informed as to the status of such patent matters, including by providing
Sunesis with (i) copies of any documents relating to Sunesis Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents which Millennium receives from any patent office within twenty (20) days of receipt thereof, including notice
of all interferences, reissues, reexaminations, oppositions or requests for patent term extensions, and (ii) the opportunity to review and comment on any documents relating to Sunesis Collaboration Patents and Joint Sunesis-Biogen Collaboration
Patents which will be filed in any patent office as soon practicable but in all cases at least twenty (20) days prior to such filing. All costs associated with filing, prosecuting, issuing and maintaining patent applications and patents within
the Sunesis Core Technology shall be borne by Sunesis. In conducting the prosecution activities described in this Section 13.5.2(b), each Party shall employ reasonable efforts not to substantially negatively impact the other Party’s rights
under the surviving provisions of this Agreement. 
 (c) Sunesis’s rights and obligations under Section 2.2.3 shall
survive with respect to Co-Funded Products for which Sunesis has exercised its Co-Funding Option prior to such termination, and Millennium shall pay royalties on any such Co-Funded Products in accordance with Section 6.3.2. Millennium shall no
longer be obligated to provide the detailed plans required of a Co-Development Plan and Budget to Sunesis, but shall provide Sunesis with annual budgets of post Phase I Development Costs for any such Co-Funded Products. Sunesis’s Co-Funding
Option with respect to future Licensed Products shall terminate, as will Article 3, as well as Sunesis’s right to participate in the JDC under Section 4.3 and any Licensed Product Teams under Section 2.3. 

13.5.3 Termination by Sunesis for Breach or Bankruptcy of Millennium. In the event of any termination by Sunesis pursuant to
Section 13.2 due to Millennium’s breach or pursuant to Section 13.3 for Millennium’s bankruptcy, in addition to those provisions surviving under Section 13.8, the following provisions of this Section 13.5.3 shall apply:

 (a) Sections 2.5.1 (Research Records); 2.5.2 (Inspections) (but only with respect to Sunesis’s rights and
Millennium’s obligations); 5.1.3 (License for Reverted Licensed 

  
 -39-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
Products); 6.1 (Research Milestones); 6.2 (Development Milestones); 6.3 (Royalties on Annual Net Sales of Licensed Products); 6.4 (Royalties on Net Sales of Reverted Licensed Products (except
that any royalties payable by Sunesis thereunder, commencing upon such termination and continuing thereafter, shall be reduced by [ * ]); 6.5 (Royalty Term); Article 8 (Diligence); Article 9 (Intellectual Property) (other than Sections 9.2.2
and 9.2.3, which shall terminate); and Exhibit 8.2 (Reverted Licensed Products) shall survive, in addition to those provisions surviving under Section 13.8. 
 (b) Subject to the rights of Biogen Idec under the Millennium-Biogen Agreement, Millennium shall control prosecution of all the Biogen Idec Collaboration Patents and Joint Sunesis-Biogen Collaboration
Patents at its own expense. Sunesis shall control prosecution of all Sunesis Collaboration Patents at its own expense. Sunesis shall be given the opportunity to review Millennium’s activities and reasonably consult with Millennium with respect
to Joint Sunesis-Biogen Collaboration Patents, and Millennium shall in good faith consider including in such patent applications such claims as Sunesis reasonably requests. Millennium shall keep Sunesis reasonably informed as to the status of such
patent matters, including by providing Sunesis with (i) copies of any documents relating to Joint Sunesis-Biogen Collaboration Patents which Millennium receives from any patent office within twenty (20) days of receipt thereof, including
notice of all interferences, reissues, reexaminations, oppositions or requests for patent term extensions, and (ii) the opportunity to review and comment on any documents relating to Joint Sunesis-Biogen Collaboration Patents which will be
filed in any patent office as soon practicable but in all cases at least twenty (20) days prior to such filing. All costs associated with filing, prosecuting, issuing and maintaining patent applications and patents within the Sunesis Core
Technology shall be borne by Sunesis. In conducting the prosecution activities described in this Section 13.5.3(b), each Party shall employ reasonable efforts not to substantially negatively impact the other Party’s rights under the
surviving provisions of this Agreement. 
 (c) Millennium’s rights with respect to Co-Funded Products and the Co-Funded
Option shall be as follows: 
 (i) With respect to any Co-Funded Product for which Sunesis has exercised its Co-Funding Option,
and for which Millennium has not obtained Regulatory Approval in any territory in the Co-Funded Territory for such Co-Funded Product, in each case as of the effective date of such termination, such Co-Funded Product shall become a Reverted Licensed
Product in accordance with Section 8.2 and Exhibit 8.2 and Sunesis shall thereafter pay royalties to Millennium on Net Sales of such Reverted Licensed Product in accordance with Section 6.4. 

(ii) With respect to any Co-Funded Product for which Sunesis has exercised its Co-Funding Option, and for which Millennium has obtained
Regulatory Approval in any territory in the Co-Funded Territory for such Co-Funded Product, in each case as of the effective date of such termination, Sunesis’s rights and obligations under Section 2.2.3 shall survive, and Millennium shall
pay royalties on any such Co-Funded Products in accordance with Section 6.3.2. Millennium shall no longer be obligated to provide the detailed plans 

  
 -40-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
required of a Co-Development Plan and Budget to Sunesis, but shall provide Sunesis with annual budgets of post Phase I Development Costs for any such Co-Funded Products. Sunesis’s Co-Funding
Option with respect to future Licensed Products shall terminate, as will Article 3, as well as Sunesis’s right to participate in the JDC under Section 4.3 and any Licensed Product Teams under Section 2.3. 

(iii) Sunesis’s Co-Funding Option under Section 2.2 with respect to future Licensed Products shall continue (i.e., with
respect to Licensed Products that are not Co-Funded Products as of the effective date of such termination), provided that Millennium shall no longer be obligated to provide for each Licensed Product the detailed plans and clinical data required of
an Initial Development Plan and Phase II Notice pursuant to Section 2.2.1. Millennium shall, however, provide Sunesis with annual budgets of post Phase I Development Costs for such Co-Funded Product in accordance with the timetable for a Phase
II Notice set forth in Section 2.2.1, and shall provide reasonable cooperation to Sunesis in evaluating such Co-Funded Product and the post Phase I Development Costs related thereto, including consulting with Sunesis in good faith regarding
such annual budgets and the financial, scientific and regulatory assumptions reflected therein. 
 13.6. Termination by
Millennium for Convenience. In the event of termination of this Agreement pursuant to Section 13.4, in addition to those provisions surviving under Section 13.8, the following shall apply: 

13.6.1 Sections 2.5.1 (Research Records); 2.5.2 (Inspections); Articles 2 (Product Development); 3 (Product Commercialization); 4
(Management); 5.1.3 (License for Reverted Licensed Products); 6.1 (Research Milestones); 6.2 (Development Milestones); 6.3 (Royalties on Annual Net Sales of Licensed Products); 6.4 (Royalties on Net Sales of Reverted Licensed Products) (except that
any royalties payable by Sunesis thereunder, commencing upon such termination and continuing thereafter, shall be reduced by [ * ]); Section 6.5 (Royalty Term); Article 8 (Diligence); Article 9 (Intellectual Property) (other than
Sections 9.2.2 and 9.2.3, which shall terminate); and Exhibit 8.2 (Reverted Licensed Products) shall survive, in addition to those provisions surviving under Section 13.8. 

13.6.2 Subject to the rights of Biogen Idec under the Millennium-Biogen Agreement, Millennium shall control prosecution of all the Biogen
Idec Collaboration Patents and Joint Sunesis-Biogen Collaboration Patents at its own expense. Sunesis shall control prosecution of all Sunesis Collaboration Patents at its own expense. Sunesis shall be given the opportunity to review
Millennium’s activities and provide input with respect to Joint Sunesis-Biogen Collaboration Patents, and Millennium shall in good faith consider including in such patent applications such claims as Sunesis reasonably requests. Millennium shall
keep Sunesis reasonably informed as to the status of such patent matters, including by providing Sunesis with (i) copies of any documents relating to Joint Sunesis-Biogen Collaboration Patents which Millennium receives from any patent office
within twenty (20) days of receipt thereof, including notice of all interferences, reissues, reexaminations, oppositions or requests for patent term extensions, and (ii) the opportunity to review and comment on any documents relating to
Joint Sunesis-Biogen Collaboration Patents which will be filed in any patent office as soon practicable 

  
 -41-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
but in all cases at least twenty (20) days prior to such filing. All costs associated with filing, prosecuting, issuing and maintaining the Sunesis Core Technology shall be borne by Sunesis.
In conducting the prosecution activities described in this Section 13.6.2, each Party shall employ reasonable efforts not to substantially negatively impact the other Party’s rights under the surviving provisions of this Agreement.

 13.6.3 Millennium’s rights with respect to Co-Funded Products and the Co-Funded Option shall be as follows: 

(a) With respect to any Co-Funded Product for which Sunesis has exercised its Co-Funding Option, and for which Millennium has not
obtained Regulatory Approval in any territory in the Co-Funded Territory for such Co-Funded Product, in each case as of the effective date of such termination, such Co-Funded Product shall become a Reverted Licensed Product in accordance with
Section 8.2 and Exhibit 8.2 and Sunesis shall thereafter pay royalties to Millennium on Net Sales of such Reverted Licensed Product in accordance with Section 6.4. 
 (b) With respect to any Co-Funded Product for which Sunesis has exercised its Co-Funding Option, and for which Millennium has obtained Regulatory Approval in any territory in the Co-Funded Territory for
such Co-Funded Product, in each case as of the effective date of such termination, Sunesis’s rights and obligations under Section 2.2.3 shall survive, and Millennium shall pay royalties on any such Co-Funded Products in accordance with
Section 6.3.2. Millennium shall no longer be obligated to provide the detailed plans required of a Co-Development Plan and Budget to Sunesis, but shall provide Sunesis with annual budgets of post Phase I Development Costs for any such Co-Funded
Products. Sunesis’s Co-Funding Option with respect to future Licensed Products shall terminate, as will Article 3, as well as Sunesis’s right to participate in the JDC under Section 4.3 and any Licensed Product Teams under
Section 2.3. 
 (c) Sunesis’s Co-Funding Option under Section 2.2 with respect to future Licensed Products shall
continue (i.e., with respect to Licensed Products that are not Co-Funded Products as of the effective date of such termination), provided that Millennium shall no longer be obligated to provide for each Licensed Product the detailed plans and
clinical data required of an Initial Development Plan and Phase II Notice pursuant to Section 2.2.1. Millennium shall, however, provide Sunesis with annual budgets of post Phase I Development Costs for such Co-Funded Product in accordance with
the timetable for a Phase II Notice set forth in Section 2.2.1, and shall provide reasonable cooperation to Sunesis in evaluating such Co-Funded Product and the post Phase I Development Costs related thereto, including consulting with Sunesis
in good faith regarding such annual budgets and the financial, scientific and regulatory assumptions reflected therein. 
 13.7.
Transition of Information and Materials. With respect to a Party’s obligation to transition Collaboration Technology, information and material with respect to a particular Licensed Compound, each Party shall cooperate fully (and cause
its Affiliates to cooperate fully) with the other Party to facilitate a smooth and prompt transition of Collaboration Technology, 

  
 -42-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
information and materials that are necessary or useful for the receiving Party to exercise its licensed rights hereunder with respect to such Licensed Compound. 

13.8. Survival Sections. In addition to the provisions set forth in Sections 13.5.2, 13.5.3 and 13.6 above, as applicable, the
following provisions shall survive the expiration or termination of this Agreement for any reason: Articles 1 (Definitions), 7 (Payments, Books and Records), 10 (Confidentiality), 11 (Representations and Warranties), 12 (Indemnification), 13
(Term and Termination), 14 (Dispute Resolution) and 15 (Miscellaneous); and Sections 5.1.1 and 5.1.2. 
 ARTICLE 14

 DISPUTE RESOLUTION 
 14.1. Escalation to Senior Executives. In the event of a dispute or matter of significant concern arises between the Parties, then at the request of either Party, the matter shall be escalated to a
senior executive from each Party. Such senior executive shall be either the CEO of such Party, or another senior executive of such Party who both reports to the CEO and who has direct management responsibility for the matter in dispute. Upon such
request, such senior executives shall make themselves reasonably available to meet, and shall meet either by telephone or if, specifically requested, in person, to attempt to resolve such matter, and shall thereafter continue to use good faith
efforts to attempt to resolve such matter unless it becomes clear that the matter cannot be resolved by mutual agreement. Thereafter either Party may pursue such legal process as is otherwise available under applicable law. 

14.2. Injunctive Relief. This Article 14 shall not be construed to prohibit either Party from seeking preliminary or permanent
injunctive relief, restraining order or degree of specific performance in any court of competent jurisdiction to the extent not prohibited by this Agreement. For avoidance of doubt, any such equitable remedies provided under this Article 14 shall be
cumulative and not exclusive and are in addition to any other remedies, which either Party may have under this Agreement or applicable law. 
 14.3. Matters to Proceed to Court. Notwithstanding the foregoing, any dispute relating to the determination of validity of a Party’s patents or other issues relating solely to a Party’s
intellectual property and any dispute asserting breach of this Agreement or of the representations and warranties made hereunder shall be submitted exclusively to the federal court in Delaware, and the Parties hereby consent to the jurisdiction and
venue of such court. 
 ARTICLE 15 
 MISCELLANEOUS 
 15.1. Governing Laws. This Agreement and any dispute
arising from the construction, performance or breach hereof shall be governed by and construed, and enforced in accordance with, the laws of the state of Delaware, without reference to conflicts of laws principles. 

  
 -43-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 15.2. Waiver. It is agreed that no waiver by either Party hereto of any breach or
default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent or similar breach or default. 
 15.3. Assignment. This Agreement shall not be assignable by either Party without the written consent of the other Party hereto, except either Party may assign this Agreement without such consent to
its Affiliates, or to an entity that acquires all or substantially all of the business or assets of such Party whether by merger, reorganization, acquisition, sale, or otherwise; provided, however, that the assignee shall agree in writing to be
bound by the terms and conditions of this Agreement. Notwithstanding any other provision in this Agreement, [ * ] involving Sunesis shall not be deemed to be a breach of this Agreement or otherwise require [ * ], provided that such
[ * ] shall not [ * ] to the Sunesis Licensed Patents and Sunesis Core Technology with respect to: the [ * ]; Biogen Idec Collaboration Patents; Joint Sunesis-Biogen Collaboration Patents; Development Technology; Other
Millennium Technology; and Confidential Information of Millennium. 
 15.4. Independent Contractors. The relationship of
the Parties hereto is that of independent contractors. The Parties hereto are not deemed to be agents, partners or joint venturers of the others for any purpose as a result of this Agreement or the transactions contemplated thereby. 

15.5. Compliance with Laws. In exercising their rights under this license, the Parties shall fully comply in all material respects
with the requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this license including those applicable to the development, manufacture, distribution,
import and export and sale of Products pursuant to this Agreement. 
 15.6. Patent Marking. Millennium agrees to mark and
use reasonable efforts to make all its Sublicensees mark all Licensed Products sold pursuant to this Agreement in accordance with the applicable statute or regulations relating to patent marking in the country or countries of manufacture and sale
thereof. Sunesis agrees to mark and use reasonable efforts to make its Sublicensees mark all Reverted Licensed Products sold pursuant to this Agreement in accordance with the applicable statute or regulations relating to patent marking in the
country or countries of manufacture and sale thereof. 
 15.7. Notices. All notices, requests and other communications
hereunder shall be in writing and shall be personally delivered or by registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be specified in
writing to the other Parties hereto and shall be deemed to have been given upon receipt: 
  

			
	Sunesis:	  	 Sunesis Pharmaceuticals, Inc.

395 Oyster Point Boulevard, Suite 400
 South San
Francisco, California 94080
 Attn:       Chief Executive Officer

  
 -44-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

			
	With a copy to:	  	 Cooley LLP
 3175 Hanover
St.
 Palo Alto, California 94304-1050

Attn:       Glen Sato

		
	Millennium	  	 Millennium Pharmaceuticals, Inc.
 40 Landsdowne Street
 Cambridge, Massachusetts 02139

Attn:       General Counsel

		
	With a copy to:	  	 Millennium Pharmaceuticals, Inc.
 40 Landsdowne Street
 Cambridge, Massachusetts 02139

Attn:       Chief Medical Officer

 15.8. Severability. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue
in full force and effect to the fullest extent permitted by law without said provision, and the Parties shall amend the Agreement to the extent feasible to lawfully include the substance of the excluded term to as fully as possible realize the
intent of the Parties and their commercial bargain. If a Party seeks to avoid a provision of this Agreement by asserting that such provision is invalid, illegal or otherwise unenforceable, the other Party shall have the right to terminate this
Agreement upon sixty (60) days’ prior written notice to the asserting Party, unless such assertion is eliminated and cured within such sixty (60) day period. If Millennium has sought to so avoid a provision of this Agreement, such
termination shall be deemed a termination by Millennium under Section 13.4 above, and if Sunesis has sought such an avoidance, such termination shall be deemed a termination by Millennium for breach by Sunesis under Section 13.2 above.

 15.9. Advice of Counsel. Sunesis and Millennium have each consulted counsel of their choice regarding this Agreement,
and each acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and will be construed accordingly. 
 15.10. Performance by Affiliates; Warranty. Millennium may exercise any right or discharge any obligation hereunder through any of its Affiliates. Each Party hereby warrants and guarantees the
performance of any and all rights and obligations of this Agreement by its Affiliates and Sublicensees. 
 15.11. Complete
Agreement. This Agreement with its Exhibits, together with the Three Party Agreement, constitutes the entire agreement, both written and oral, between the Parties with respect to the subject matter hereof, and all prior agreements respecting the
subject matter hereof, either written or oral, express or implied, shall be abrogated, canceled, and are null and void and of no effect. No amendment or change hereof or addition hereto shall be effective or binding on either of the Parties hereto
unless reduced to writing and executed by the respective duly authorized representatives of Sunesis and Millennium. 

  
 -45-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 15.12. Headings. The captions to the several Sections and Articles hereof are not
a part of this Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation. 
 15.13. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.

  
 -46-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed by their
authorized representatives and delivered in duplicate originals as of the Effective Date. 
  

									
	MILLENNIUM PHARMACEUTICALS, INC.	 		  	SUNESIS PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Deborah Dunsire, M.D.
	 		  	By:	 	 /s/ Daniel N. Swisher, Jr.

									
					
	Name:	 	 Deborah Dunsire, M.D.
	 		  	Name:	 	 Daniel N. Swisher, Jr.

					
	Title:	 	 Chief Executive Officer
	 		  	Title:	 	 Chief Executive Officer

  
 -47-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 EXHIBIT 1.4 

Collaboration Patents 
 RAF Portfolio 
  

																									
	 Country
	  	Case
Type	 	Status	 	 Title
	  	Filing Date	 	 	 Application

Number
	  	Patent
Number	 	  	Grant
Date	 	  	Publication
Number	 	Publication
Date
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  	[ * ]	 	[ * ]
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  	[ * ]	 	[ * ]
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  	[ * ]	 	[ * ]
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  	[ * ]	 	[ * ]
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  	[ * ]	 	[ * ]
	 [ * ] 
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  				  				  		 	

  
 -48-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

																					
	 Country
	  	Case
Type	 	Status	 	 Title
	  	Filing Date	 	 	 Application

Number
	  	Patent
Number	 	Grant
Date	 	Publication
Number	 	Publication
Date
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ]	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ]	  		 		 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ] 	  	 	[ 	* ] 	 	[ * ] 	  		 		 	[ * ]	 	[ * ]

  
 -49-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 [ * ] Portfolio 

 

																			
	 Program
	  	Docket
Number	 	Country	 	Case
Type	 	Status	 	 Title
	  	Filing
Date	 	 Application

Number
	  	Publication
Number	 	Publication
Date
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ]
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  		 	
	 [ * ]
	  	[ * ]	 	[ * ]	 	[ * ]	 	[ * ]	 	[ * ] 	  	[ * ]	 	[ * ] 	  		 	

  
 -50-

 EXHIBIT 1.41 
 Sunesis Core Technology 
  

							
	 Sunesis

No.
	  	 Serial No.
	  	 Title
	  	 Status

	 SU-100
	  	 US
 09/105,372
	  	Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to Biological Target Molecules	  	Issued as U.S. Patent No. 6,335,155
				
	 SU-100

D1C1
	  	 US
 10/043,833
	  	Methods for Rapidly Identifying Small Organic Molecule Ligands for Binding to Biological Target Molecules	  	allowed
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

							
	 Sunesis

No.
	  	 Serial No.
	  	 Title
	  	 Status

	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]

  
 -52-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

							
	 Sunesis

No.
	  	 Serial No.
	  	 Title
	  	 Status

	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
				
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
				
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
				
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
				
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
				
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
				
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
				
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
				
	[ * ]	  		  	[ * ]	  	[ * ]
				
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
				
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
				
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]

  
 -53-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 EXHIBIT 1.44 

[ * ] Target Selectivity 

[ * ] 
  

									
	 Name
	  	 Units/Amount
	  	 Source
	  	 Catalog Number
	  	 Storage

	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]oC
					
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]oC
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]oC
					
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]oC, [ * ]
					
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]oC
					
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]oC
					
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]oC
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]oC

 [ * ] 
 [ * ] Cellular Assay [ * ] 
 [ * ] 

[ * ] Cellular Assay [ * ] 
 [ * ]

  

																									
	 	  	 1
	  	 2
	  	 3

[ * ]
	  	 4

[ * ]
	  	 5

[ * ]
	  	 6

[ * ]
	  	 7

[ * ]
	  	 8

[ * ]
	  	 9

[ * ]
	  	 10

[ * ]
	  	 11
	  	 12

													
	 ARTICLE 16A
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]

  
 -54-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 [ * ] Enzyme Assay [ * ] 
 [ * ] 
  

																									
	 	  	 1
	  	 2
	  	 3
	  	 4
	  	 5
	  	 6
	  	 7
	  	 8
	  	 9
	  	 10
	  	 11
	  	 12

													
	ARTICLE 17A	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]
													
	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]	  	[ * ]

 [ * ]. 

  
 -55-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 EXHIBIT 8.2 

Reverted Licensed Product 
 Section 1. Reverted Licensed Product. 
 1.1 Millennium shall
cooperate fully with Sunesis and shall provide Sunesis with all data, documentation, information and materials generated or used by Millennium in the development, production or other exploitation of such Reverted Licensed Product, and Sunesis shall
have the right to use and disclose such items. 
 1.2 To the extent not already terminated, the licenses granted to Millennium
under Section 5.1 shall terminate with respect to such Reverted Licensed Product. 
 1.3 All right, title and interest in
and to (i) all regulatory filings related to the Reverted Licensed Product, including all INDs, NDAs and all information and correspondence related thereto, and (ii) any trademarks specific to the Reverted Licensed Product shall be
transferred and assigned to Sunesis. 
 1.4 Millennium shall cooperate fully with Sunesis upon Sunesis’s request to assign
to Sunesis, or otherwise secure for Sunesis the benefits of, any arrangement between Millennium and a Third Party related to the development, production or exploitation of such Reverted Licensed Product, including clinical research agreements,
manufacturing and supply agreements and distribution agreements. In the event that such Reverted Licensed Product was manufactured by Millennium, then Millennium shall continue to provide Sunesis at fully loaded cost plus a 15% cost of capital
charge with quantities of Reverted Licensed Products reasonably ordered by Sunesis within twelve (12) months after the date of transition. 
 1.5 Without limiting the foregoing, Millennium shall use reasonable efforts to implement the provisions of this Exhibit 8.2 and to ensure orderly transition and uninterrupted development of the Reverted
Licensed Product. Sunesis shall promptly reimburse Millennium’s reasonable out-of-pocket costs with respect to activities, services and materials provided by Millennium under Section 1 of this Exhibit 8.2. 

Section 2. Termination of a Reverted Licensed Product and Reversion to Millennium. 

2.1 Sunesis shall cooperate fully with Millennium and shall provide Millennium with all data, documentation, information and materials
generated or used by Sunesis in the development, production or other exploitation of such Reverted Licensed Product, and Millennium shall have the right to use and disclose such items. 

2.2 All right, title and interest in and to (i) all regulatory filings related to such Reverted Licensed Product, including all
INDs, NDAs and all information and correspondence related thereto, and (ii) any trademarks specific to the Reverted Licensed Product shall be transferred and assigned to Millennium. 

  
 -56-

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 2.3 Sunesis shall cooperate fully with Millennium upon Millennium’s request to
assign to Millennium, or otherwise secure for Millennium the benefits of, any arrangement between Sunesis and a Third Party related to the development, production or exploitation of such Reverted Licensed Product, including clinical research
agreements, manufacturing and supply agreements and distribution agreements. In the event that such Reverted Licensed Product was manufactured by Sunesis, then Sunesis shall continue to provide Millennium at fully loaded cost plus a 15% cost of
capital charge with quantities of such Reverted Licensed Product reasonably ordered by Millennium within twelve (12) months after the date of transition. 
 2.4 Without limiting the foregoing, Sunesis shall use reasonable efforts to implement the provisions of this Exhibit 8.2 and to ensure orderly transition and uninterrupted development of such Reverted
Licensed Product. Millennium shall promptly reimburse Sunesis’s reasonable out-of-pocket costs with respect to activities, services and materials provided by Sunesis under Section 2 of this Exhibit 8.2. 

  
 -57-Termination and Transition Agreement

 Exhibit 10.6 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT
OF 1934, AS AMENDED. 
 TERMINATION AND TRANSITION AGREEMENT 
 This TERMINATION AND TRANSITION AGREEMENT (the “Agreement”), effective as of March 31, 2011 (the “Effective Date”), is made by and between Sunesis Pharmaceuticals,
Inc., a Delaware corporation, having a principal place of business at 395 Oyster Point Boulevard, Suite 400, South San Francisco, CA (“Sunesis”), Biogen Idec MA Inc., a Massachusetts corporation, having a principal place of business
at 14 Cambridge Center, Cambridge, MA (“Biogen Idec”), and Millennium Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 40 Landsdowne Street, Cambridge, MA (“MPI”). Sunesis,
Biogen Idec and MPI are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 
 BACKGROUND 
 A. Sunesis and Biogen Idec entered into a Collaboration Agreement, effective
as of August 27, 2004 (the “Original Agreement Effective Date”), as amended by a letter agreement dated June 9, 2008 and a Second Amendment dated June 19, 2009 (such Collaboration Agreement, as so amended, the
“Original Agreement”), pursuant to which Sunesis and Biogen Idec agreed to collaborate to discover and develop small molecules that modulate certain Targets (as defined in the Original Agreement). 

B. Pursuant to the research activities under the Original Agreement, Sunesis and Biogen Idec identified certain compounds which inhibit the Raf Target,
the [ * ] Target or the [ * ] Target. 
 C. Biogen Idec desires to continue to develop the [ * ] program identified
pursuant to the Original Agreement, but desires to terminate, and MPI desires to acquire all rights with respect to, the Raf and [ * ] programs identified pursuant to the Original Agreement. 

D. Sunesis agrees that (i) Biogen Idec may continue to develop the [ * ] program identified pursuant to the Original Agreement, and
(ii) Biogen Idec may terminate, and MPI may acquire all rights with respect to, the Raf and [ * ] programs identified pursuant to the Original Agreement. 
 E. Sunesis and Biogen Idec are entering into the BI/S Agreement, pursuant to which Biogen Idec will continue to develop the [ * ] program identified pursuant to the Original Agreement. 

F. Biogen Idec and MPI are entering into the Asset Transfer Agreement (the “Asset Transfer Agreement”) pursuant to which Biogen Idec is
transferring to MPI certain assets related to the Raf and [ * ] programs. 
 G. Sunesis and MPI are entering into the MPI/S Agreement,
pursuant to which MPI will continue to develop the Raf and [ * ] programs identified pursuant to the Original Agreement. 

NOW, THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, it is agreed by and between
the Parties as follows: 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 ARTICLE 1 
 DEFINITIONS 
 As used herein, the following terms will have the meanings set forth below:

 1.1 “Affiliate” means, with respect to a Person, any corporation or other business entity which controls, is
controlled by or is under common control with such Person but only for so long as such entity controls, is controlled by, or is under common control with such Person. For purposes of this definition, “control” shall mean the
ownership directly or indirectly of fifty percent (50%) or more of the stock entitled to vote for the election of directors, and for nonstock organizations, of the equity interests entitled to control the management of such entity. [ *
]. 
 1.2 “BI/S Agreement” shall mean the Amended and Restated Collaboration Agreement between Biogen Idec
and Sunesis, in the form attached hereto as Exhibit A. 
 1.3 “[ * ] Target” means the human
protein [ * ]. 
 1.4 “Business Day” means a day on which the banks in Boston, Massachusetts are open
for business. 
 1.5 “Governmental Authority” means any multi-national, federal, state, local, municipal or
other government authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). 

1.6 “Law” means any law, statute, rule, regulation, ordinance, or any ruling, writ, injunction, order, judgment or
decree of any court, or other pronouncement having the effect of law, of any federal, national, multinational, state, provincial, county, city or other political subdivision, including (a) rules, regulations and requirements of the United
States Food and Drug Administration and any successor agency thereto and other applicable regulatory authorities, (b) the Foreign Corrupt Practices Act of 1977, as amended, or any comparable laws in any country, and (c) all export control
laws. 
 1.7 “MPI/S Agreement” shall mean the License Agreement between MPI and Sunesis, in the form attached
hereto as Exhibit B. 
 1.8 “New Agreement” shall mean each of the BI/S Agreement and the MPI/S
Agreement; “New Agreements” shall mean the BI/S Agreement and the MPI/S Agreement, collectively. 
 1.9
“[ * ] Target” means human [ * ]. 
 1.10 “Person” means any natural person,
corporation, general partnership, limited partnership, joint venture, proprietorship or other business organization or a Governmental Authority. 

  
 2 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 1.11 “Raf Target” means the human Raf protein kinase together with the
Raf protein family members [ * ]. 
 1.12 “Target” means the Raf Target or the [ * ] Target.

 1.13 “Third Party” shall mean any Person other than Sunesis, MPI and Biogen Idec, and their respective
Affiliates. 
 1.14 Additional Terms. In addition to the foregoing, the following terms shall have the meaning defined in
the corresponding Section below: 
  

			
	 Definition
	  	 Section Defined

	Agreement	  	Preamble
		
	Biogen Idec	  	Preamble
		
	Effective Date	  	Preamble
		
	Effective Time	  	2.1
		
	Indemnitee	  	6.2
		
	Indemnitor	  	6.2
		
	Liabilities	  	6.1
		
	MPI	  	Preamble
		
	Original Agreement	  	Background
		
	Original Agreement Effective Date	  	Background
		
	Party, Parties	  	Preamble
		
	Representing Party	  	3.1
		
	Sunesis	  	Preamble

 1.15 Construction. In
construing this Agreement, unless expressly specified otherwise; 
 1.15.1 references to Sections, Articles and Exhibits are to
sections and articles of, and exhibits to, this Agreement; 
 1.15.2 except where the context otherwise requires, use of any
gender includes any other gender, and use of the singular includes the plural and vice versa; 
 1.15.3 any list or examples
following the word “including” shall be interpreted without limitation to the generality of the preceding words; 

  
 3 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 1.15.4 except where the context otherwise requires, the word “or” is used in
the inclusive sense; and 
 1.15.5 all references to “dollars” or “$” herein shall mean U.S. Dollars.

 ARTICLE 2 
 TERMINATION AND EFFECTIVENESS 
 2.1 Amendment and Restatement of
Original Agreement. The Original Agreement shall be amended and restated in its entirety (in the form of the BI/S Agreement) as of 9:00 pm, Eastern Daylight Time, on the Effective Date (such time, the “Effective Time”).

 2.2 Effectiveness of Asset Transfer Agreement. The Asset Transfer Agreement shall be deemed to have been entered into
and to become effective immediately after the Effective Time. 
 2.3 Effectiveness of MPI/S Agreement. The MPI/S
Agreement shall be deemed to have been entered into and to become effective immediately after the effectiveness of the Asset Transfer Agreement pursuant to Section 2.2. 
 2.4 Deliveries upon Execution. 
 2.4.1 Contemporaneously with the execution
of this Agreement, Biogen Idec shall: 
 (a) execute and deliver to Sunesis the BI/S Agreement; and 

(b) execute and deliver to MPI the Asset Transfer Agreement. 
 2.4.2 Contemporaneously with the execution of this Agreement, MPI shall: 
 (a)
execute and deliver to Biogen Idec the Asset Transfer Agreement; and 
 (b) execute and deliver to Sunesis the MPI/S Agreement.

 2.4.3 Contemporaneously with the execution of this Agreement, Sunesis shall: 

(a) execute and deliver to Biogen Idec the BI/S Agreement; and 

(b) execute and deliver to MPI the MPI/S Agreement. 

  
 4 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 ARTICLE 3 
 REPRESENTATIONS AND WARRANTIES 
 3.1 Mutual. Each Party (the
“Representing Party”) hereby represents and warrants to each other Party, on behalf of the Representing Party and on behalf of its Affiliates, that: 
 3.1.1 As of as of the Effective Date, the Representing Party is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized. 

3.1.2 As of the Effective Date, it has the legal power and authority to enter into this Agreement and to perform all of its obligations
hereunder. 
 3.1.3 As of the Effective Date, this Agreement is a legal and valid obligation binding upon it and enforceable in
accordance with its terms. 
 3.1.4 All necessary consents, approvals and authorizations of all Governmental Authorities and
other Persons required to be obtained by the Representing Party in connection with this Agreement have been obtained as of the Effective Date. 
 3.1.5 As of the Effective Date, the execution and delivery of this Agreement and the performance of the Representing Party’s obligations hereunder taken together with any obligations under the New
Agreements (a) do not conflict with or violate any requirement of applicable Laws; and (b) do not conflict with, or constitute a default under, any other contractual obligation of the Representing Party. After the Effective Date, the
Representing Party will not enter into any agreement with any other Party, any Affiliate of a Party or any Third Party that conflicts with the terms of this Agreement. 
 3.1.6 No Claims Under Original Agreement. Neither Biogen Idec nor Sunesis will make any claim against the other arising from any alleged breach of the Original Agreement as it existed prior to the
Effective Date. 
 3.2 Sunesis. Sunesis represents and warrants to MPI and Biogen Idec as of the Effective Date, and
covenants to MPI and Biogen Idec, that: 
 3.2.1 Sunesis has no actual, planned or threatened claim, demand or proceeding itself
or through an Affiliate against Biogen Idec or an Affiliate of Biogen Idec, and has no knowledge of any actual, planned or threatened claim, demand or proceeding by a Third Party, arising out of the Original Agreement or otherwise related to the
Assigned Assets (as defined in the Asset Transfer Agreement). 
 3.2.2 Sunesis will not make any claim against MPI arising from
any alleged breach of (a) the Original Agreement as it existed prior to the Effective Date by Biogen Idec or (b) this Agreement by Biogen Idec with respect to the transactions contemplated by this Agreement. 

  
 5 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 3.2.3 Sunesis will not make any claim against (a) Biogen Idec arising from any
alleged breach of this Agreement or the MPI/S Agreement by MPI, or (b) MPI arising from any alleged breach of the BI/S Agreement by Biogen Idec. 
 3.3 Knowledge. Where a representation or warranty contained in this Article 3 is stated to be to a Party’s knowledge, this shall mean to the actual knowledge of all of the then current
officers and appropriate personnel at the director or greater level having had responsibility for the efforts of such Party or its Affiliates with respect to Targets. 
 3.4 Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT OR THE NEW AGREEMENTS, NO PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH
RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR VALIDITY OF ANY INTELLECTUAL PROPERTY. IN NO EVENT WILL ANY PARTY BE LIABLE TO ANY OTHER PARTY FOR ANY
SPECIAL, INDIRECT, CONSEQUENTIAL, INCIDENTAL, OR PUNITIVE DAMAGES ARISING UNDER OR AS A RESULT OF THIS AGREEMENT (OR THE TERMINATION HEREOF) INCLUDING THE LOSS OF PROSPECTIVE PROFITS OR ANTICIPATED SALES, OR ON ACCOUNT OF EXPENSES, INVESTMENTS, OR
COMMITMENTS IN CONNECTION WITH THE BUSINESS OR GOODWILL OF SUCH PARTY OR OTHERWISE. 
 3.5 [ * ]. 

ARTICLE 4 

PAYMENT TO SUNESIS 
 In full consideration for Sunesis’s entry into the New Agreements and this Agreement, all of the rights granted to MPI by Sunesis under this Agreement, and the obligations of Sunesis to MPI under
this Agreement, including the consent by Sunesis for Biogen Idec to sell the Assigned Assets (as defined in the Asset Transfer Agreement) and license the Licensed IP (as defined in the Asset Transfer Agreement) to MPI pursuant to the Asset Transfer
Agreement, MPI shall make a non-creditable, non-refundable payment to Sunesis by wire transfer in the amount of Four Million Dollars ($4,000,000) within two (2) Business Days after the Effective Date. 

ARTICLE 5 

CONFIDENTIALITY 
 5.1 Nondisclosure of Financial Terms or Exhibits. Each of the Parties agrees not to disclose the Exhibits or the financial terms of this Agreement to any Third Party without the prior written
consent of the other Parties, which consent shall not be unreasonably withheld, except (a) to such Party’s attorneys, advisors, investors, potential bona fide collaborators, licensees and sublicensees, and others on a need to know basis,
under circumstances that reasonably protect the confidentiality thereof; (b) to the extent required by Law; or (c) to the extent required in filings required to be made with, (and with appropriate requests made for 

  
 6 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
confidential treatment) the Securities and Exchange Commission or any national securities exchange; provided, however, that, with respect to any filing required to made with the
Securities and Exchange Commission or any national securities exchange, the Party subject to such filing requirement shall, at least ten (10) Business Days in advance of any such filing, provide the other Parties with a draft set of redactions
to this Agreement for which confidential treatment will be sought, incorporate each other Party’s comments as to additional terms it would like to see redacted, and seek confidential treatment for such additional terms (except only in the
limited circumstances where confidential treatment is manifestly unavailable). Notwithstanding the foregoing, (i) the Parties will confer promptly following the Effective Date regarding the terms of a press release related to this Agreement,
and (ii) each Party may thereafter disclose the information contained in such press release without the consent of any other Party. 
 ARTICLE 6 
 INDEMNIFICATION 

6.1 Sunesis. Subject to the limitations of liability set forth in Section 3.4, MPI and Biogen Idec agree to indemnify Sunesis
and its Affiliates and their respective directors, officers, employees and agents from and against any claims, damages or liabilities (including reasonable attorneys’ fees) (collectively, “Liabilities”) resulting from any
claim, demand, action or other proceeding (x) which [ * ], (y) in which Sunesis is [ * ] and (z) which proceeding is [ * ]; except, in each case, to the extent such Liabilities result from a material breach of
this Agreement by Sunesis or the willful misconduct (including criminal activity) of Sunesis or any of its agents or employees. 

6.2 Procedure. If a Party (the “Indemnitee”) intends to claim indemnification under this Article 6, it shall
promptly notify the other Party (the “Indemnitor”) in writing of any claim, demand, action or other proceeding for which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have the right to participate
in, and, to the extent the Indemnitor so desires, to assume the defense thereof with counsel mutually satisfactory to such Parties; provided, however, that an Indemnitee shall have the right to retain its own counsel, with the fees and
expenses to be paid by the Indemnitor, if representation of such Indemnitee by the counsel retained by the Indemnitor would be inappropriate due to actual or potential differing interests between the Indemnitee and any other Party represented by
such counsel in such proceeding. The obligations of this Article 6 shall not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of the Indemnitor, which consent
shall not be withheld or delayed unreasonably. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve the
Indemnitor of its obligation to the Indemnitee under this Article 6 to the extent of such prejudice. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnitor and its legal representatives, at the Indemnitor’s
sole cost and expense, in the investigation of any claim, demand, action or other proceeding covered by this Article 6 and shall permit the Indemnitor to have sole control and authority with respect to the defense and settlement of any such claim,
demand, action or other proceeding. The Indemnitor shall not, without the Indemnitee’s consent, which consent shall not be withheld or delayed unreasonably, consent to the entry of any 

  
 7 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 
judgment or accept any settlement with respect to such claim, demand, action or proceeding which imposes liability not covered by this indemnification or restrictions on the Indemnitee.

 ARTICLE 7 
 DISPUTE RESOLUTION 
 7.1 Escalation to Senior Executives. In the
event of a dispute or matter of significant concern arises between two or more Parties, then at the request of one of such Parties, the matter shall be escalated to a senior executive from each Party affected by such matter. Such senior executive
shall be either the CEO of such Party, or another senior executive of such Party designated by the CEO. Upon such request, such senior executives shall make themselves reasonably available to meet, and shall meet either by telephone or if,
specifically requested, in person, to attempt to resolve such matter, and shall thereafter continue to use good faith efforts to attempt to resolve such matter within thirty (30) days after such matter is referred to them. If such senior
executives are not able to resolve such dispute within thirty (30) days after such matter is referred to them, then any Party in the dispute may pursue such legal process as is otherwise available under applicable law; provided that such Party
shall use commercially reasonable efforts to give notice to all Parties hereunder upon the filing of any court action related to such dispute. 
 7.2 Injunctive Relief. This Article 7 shall not be construed to prohibit any Party from seeking preliminary or permanent injunctive relief, restraining order or degree of specific performance in
any court of competent jurisdiction to the extent not prohibited by this Agreement. For avoidance of doubt, any such equitable remedies provided under this Article 7 shall be cumulative and not exclusive and are in addition to any other remedies
which either Party may have under this Agreement or applicable Law. 
 7.3 Choice of Venue. Notwithstanding the
foregoing, solely to the extent that any intellectual property matter is not otherwise subject to either the MPI/S Agreement or BI/S Agreement (in which event such matter will be governed by the applicable agreement), any dispute relating to the
determination of validity of a Party’s patents or other issues relating solely to a Party’s intellectual property and any dispute asserting breach of this Agreement or of the representations and warranties made hereunder shall be submitted
exclusively to the state or federal courts in the county of [ * ], and the Parties hereby consent to the jurisdiction and venue of such court. 
 ARTICLE 8 
 MISCELLANEOUS 

8.1 Governing Laws. This Agreement and any dispute arising from the construction, performance or breach hereof shall be governed
by and construed, and enforced in accordance with, the Laws of the state of [ * ], without reference to its conflicts of laws principles. 
 8.2 Waiver. It is agreed that no waiver by a Party of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent and/or similar
breach or default. 

  
 8 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 8.3 Assignment. This Agreement shall not be assignable by a Party without the
written consent of the other Parties, except a Party may assign this Agreement without such consent to its Affiliates, or to an entity that acquires all or substantially all of the business or assets of such Party, whether by merger, reorganization,
acquisition, sale, or otherwise; provided, however, that the assignee shall agree in writing to be bound by the terms and conditions of this Agreement. 
 8.4 Independent Contractors. The relationship of the Parties is that of independent contractors. The Parties are not deemed to be agents, partners or joint venturers of each other for any purpose
as a result of this Agreement or the transactions contemplated thereby. 
 8.5 Notices. All notices, requests and other
communications hereunder shall be in writing and shall be personally delivered or by registered or certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below, or such other address as may be
specified in writing to the other Parties hereto and shall be deemed to have been given upon receipt: 
  

			
	Sunesis:	  	 Sunesis Pharmaceuticals, Inc.

395 Oyster Point Boulevard, Suite 400
 South San
Francisco, CA 94080
 Attn: Chief Executive Officer

		
	With a copy to:	  	 Cooley LLP
 3175 Hanover
St.
 Palo Alto, CA 94304-1050
 Attn:
Glen Sato

		
	Biogen Idec:	  	 Biogen Idec MA Inc.
 133
Boston Post Road
 Weston, MA 02493

Attn: Executive Vice President, Corporate Development

		
	With a copy to:	  	 Biogen Idec MA Inc.
 133
Boston Post Road
 Weston, MA 02493

Attn: General Counsel

		
	MPI	  	 Millennium Pharmaceuticals, Inc.
 40 Landsdowne Street
 Cambridge, MA 02139
 Attn: General Counsel

		
	With a copy to:	  	 Millennium Pharmaceuticals, Inc.
 40 Landsdowne Street
 Cambridge, MA 02139
 Attn: Chief Medical Officer

  
 9 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 8.6 Severability. In the event that any provision of this Agreement becomes or is
declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect to the fullest extent permitted by Law without said provision, and the Parties shall amend the Agreement to
the extent feasible to lawfully include the substance of the excluded term to as fully as possible realize the intent of the Parties and their commercial bargain. 
 8.7 Advice of Counsel. Sunesis, Biogen Idec and MPI have each consulted counsel of their choice regarding this Agreement, and each acknowledges and agrees that this Agreement shall not be deemed to
have been drafted by one Party or any other and will be construed accordingly. 
 8.8 Performance by Affiliates. Each
Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates
to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may
proceed directly against such Party without any obligation to first proceed against such Party’s Affiliate. 
 8.9
Complete Agreement. This Agreement with its Exhibits constitutes the entire agreement, both written and oral, between the Parties with respect to the subject matter hereof. Notwithstanding the foregoing, the Parties agree and acknowledge that
the New Agreements and the Asset Transfer Agreement shall survive the execution of this Agreement. 
 8.10 Headings. The
captions to the several Sections and Articles hereof are not a part of this Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation. 

8.11 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of
which together shall be deemed to be one and the same agreement. 
 [ * ] 

  
 10 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed by their
authorized representatives and delivered in triplicate originals as of the Effective Date. 
  

									
	BIOGEN IDEC MA INC.	  		  	SUNESIS PHARMACEUTICALS, INC.
					
	By:	 	 /s/ Paul J. Clancy
	  		  	By:	 	 /s/ Daniel N. Swisher, Jr.

									
					
	Name:	 	 Paul J. Clancy
	  		  	Name:	 	 Daniel N. Swisher, Jr.

					
	Title:	 	 Chief Financial Officer
	  		  	Title:	 	 Chief Executive Officer

		
	MILLENNIUM PHARMACEUTICALS, INC.	 	
					
	By:	 	 /s/ Deborah Dunsire, M.D.
	  		  		 	
					
	Name:	 	 Deborah Dunsire, M.D.
	  		  		 	
					
	Title:	 	 Chief Executive Officer
	  		  		 	

  
 Signature Page

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 EXHIBIT A 
 BI/S AGREEMENT 
 [ * ] 

{Note: BI/S Agreement attached to the executed version of this Exhibit 10.6 is being filed by Sunesis Pharmaceuticals, Inc. as Exhibit
10.4 to the Form 10-Q for the quarter ended March 31, 2011.} 

  
 A-1

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

 EXHIBIT B 
 MPI/S AGREEMENT 
 [ * ] 

{Note: MPI/S Agreement attached to the executed version of this Exhibit 10.6 is being filed by Sunesis Pharmaceuticals, Inc. as Exhibit
10.5 to the Form 10-Q for the quarter ended March 31, 2011.} 

  
 B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00189-of-00352.parquet"}]]